Category: EQS Newswire

EQS via SeaPRwire.com / 2026-06-18 / 17:14 UTC+8 （香港，2026 年 6月 18 日）– 亞博科技控股有限公司（香港聯交所股份代號：8279，以下簡稱「亞博科技」或「公司」）今日宣佈，公司已根據主板上市規則第9B章，正式向聯交所提交轉板上市申請[1]。 董事會認為，隨著公司業務規模持續擴大及戰略拓展不斷深化，申請轉往主板上市，將為公司下一階段的發展提供更適宜的上市平台。依託公司在數字支付、銀行業務、財富管理、跨境結算及區域金融協作等領域的多元化業務佈局，轉往主板上市將有望提升公司作為綜合金融科技集團的品牌認知度。這不僅有助於深化與用戶、商戶、金融機構、商業合作夥伴及投資者的互動與聯繫，也將助力公司把握更多業務發展機遇。 同時，主板市場擁有更廣泛的投資者基礎及更高的市場認可度，有助於提升投資者對公司的認知與信心，擴大公司在機構投資者及國際資本市場中的覆蓋範圍，進一步優化股東基礎及投資者結構，提升股份交易流動性，並為公司長遠發展提供更大的靈活性。申請轉往主板上市符合公司的發展戰略與股東的整體利益。 作為阿里巴巴集團成員公司，亞博科技致力於成為全球領先的綜合性金融科技集團，立足綜合金融業務、商業賦能及本地消費者服務業務，並積極佈局包括黃金及貴金屬交易創新技術服務等在內的新興業務領域，逐步構建覆蓋多元場景的「全鏈條、全方位金融服務」能力。2022年，公司收購澳門通股份有限公司及其附屬公司，將業務版圖拓展至支付領域；2024年，又完成對螞蟻銀行（澳門）的控股權收購，進一步夯實「支付+金融」的平台基礎。目前，公司正積極拓展創新金融業務，並於2026年初與香港黃金交易所達成合作，將為其設計、開發及維護一個安全且穩定的電子交易、清算及結算平台，助力香港國際黃金交易中心建設，並將推動黃金及貴金屬市場數字化升級。 截至2026年3月31日止年度，亞博科技總營收約7.6億港元，同比增長約23.7%，經營規模持續擴大。其中，實體與數字銀行業務表現尤為亮眼，期內收入約2.25億港元，同比大幅增長約232.7%。高增速業務佔比持續提升，收入結構進一步優化，這標誌著過去幾年來公司整體的戰略轉型已見成效。未來，公司將繼續深化金融科技生態建設，並把握粵港澳大灣區及國際市場發展機遇，穩步推進全球化業務佈局。 -完- 關於亞博科技控股有限公司 亞博科技是阿里巴巴集團成員公司，於百慕達註冊成立，其股份在GEM上市（股份代號：8279），並獲納入MSCI全球微型股指數。作為一家綜合性金融科技集團，亞博科技的核心業務大致分為四大類： (1) 綜合金融業務： (i) 數字支付業務： (a) 澳門通卡 (b) MPay (c) 商戶收單服務1 (ii) 實體與數字銀行業務： (a) 個人和中小企數字銀行服務2 (b) 財富管理服務3 (2) 商業賦能及本地消費者服務業務： 生活服務、文娛服務、為商戶提供營銷技術服務及電商平台 (3) 黃金及貴金屬交易創新技術服務 (4) 彩票業務4 1 該業務亦包含原於「支付相關硬件供應」項下呈列的業務範疇。 2 該業務包含存款、貸款、轉帳及跨境匯款、跨境電商/供應鏈融資等業務。 3 該業務包含原於「互聯網證券投資、帳戶服務、保險代理服務及客戶自助網點銀行服務」項下呈列的業務範疇。 4 該業務包含彩票硬件銷售、透過實體渠道代銷彩票及其他整合服務。 詳情請瀏覽 www.agtech.com [1] 股東及潛在投資者務請注意，轉板上市須待（其中包括）聯交所批准相關申請後方可進行。概不保證轉板上市將獲得聯交所批准及許可。因此，轉板上市可能會或可能不會進行。股東及潛在投資者於買賣股份時務請審慎行事。 2026-06-18 此新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 18/06/2026 / 17:14 UTC+8 (Hong Kong, June 18, 2026) – AGTech Holdings Limited (Stock Code: 8279 on the Stock Exchange of Hong Kong Limited, hereinafter referred to as “AGTech” or the “Company”) announced today that it has formally submitted an application to the Stock Exchange in relation to the proposed transfer of listing of the Company's Shares from GEM to the Main Board pursuant to Chapter 9B of the Main Board Listing Rules[1]. The Board believes that, as the Company continues to expand its business scale and deepen its strategic diversification, the Proposed Transfer of Listing would provide a more appropriate listing platform for the Company’s next phase of growth. In particular, taking into account the Company’s diverse business operations in areas such as digital payments, banking, wealth management, cross-border settlement and regional financial collaboration, the Board believes that a listing on the Main Board would enhance brand recognition of the Company as a comprehensive financial technology group, strengthen its engagement with users, merchants, financial institutions, business partners and investors, and support the Company’s ability to pursue commercial opportunities in its current market positioning. Meanwhile, the Main Board offers a broader investor base and higher market recognition, which will help enhance investor awareness of and confidence in the Company, expand the Company’s coverage among institutional investors and in international capital markets, further optimize its shareholder base and investor structure, improve the liquidity of its shares, and provide greater flexibility for the Company’s long-term development. On the basis of the foregoing, the Proposed Transfer of Listing is beneficial to the future growth and development of the Company and is in the overall interests of the Company and the Shareholders. As a member of Alibaba Group, AGTech Holdings is committed to becoming a leading global comprehensive financial technology group. It focuses on diversified services including full-scale financial services, commerce enablement and local consumer services, while actively expanding into emerging business areas such as innovative technology services for the gold and precious metals trading, thereby developing the capability to provide “end-to-end, all-round financial services” across diverse scenarios. In 2022, the company completed the acquisition of Macau Pass Holding Ltd. and its subsidiaries, significantly expanding its footprint into the payment sector. In 2024, it completed the attainment of the controlling stake in Ant Bank (Macau) Limited, further solidifying its “payment + finance” platform foundation. Currently, AGTech is actively broadening its innovative financial business. In early 2026, the company reached a collaboration with the Hong Kong Gold Exchange (HKGX) to design, develop and maintain a secure and stable electronic trading, clearing, and settlement platform. This initiative aims to support Hong Kong's development as an international gold trading center and drive the digital transformation of the gold and precious metals market. For the year ended March 31, 2026, AGTech recorded a total revenue of approximately HK$760 million, representing a year-on-year growth of about 23.7%, reflecting a continuous expansion in its operational scale. Notably, the full-scale banking services delivered outstanding performance, generating about HK$225 million in revenue during the year, a substantial year-on-year surge of approximately 232.7%. The rising proportion of high-growth businesses and the further optimization of the revenue structure demonstrate that the company's overall strategic transformation over the past few years has begun to materialize. Looking ahead, AGTech will continue to deepen the development of its fintech ecosystem, and capitalize on development opportunities within the Guangdong-Hong Kong-Macao Greater Bay Area and international markets to steadily advance its global business footprint. -End- ABOUT THE GROUP AGTech, as a member of the Alibaba Group, was incorporated in Bermuda and its Shares are listed on GEM (Stock Code: 8279). The Company is included as a constituent stock in the MSCI World Micro Cap Index. As a comprehensive financial technology group, AGTech’s core businesses are broadly divided into four principal categories: (1) Full-scale financial services: (i) Digital payment services: (a) mCard (b) MPay (c) Merchants acquiring services 1 (ii) Full-scale banking services: (a) Digital banking services for individuals and SMEs 2 (b) Wealth management services 3 (2) Commerce enablement and local consumer services: lifestyle, culture and entertainment, marketing technical services for merchants and e-commerce platform (3) Innovative technology services for the gold and precious metals trading (4) Lottery services 4 1 This service also includes the business line previously presented under “payment‑related hardware supply”. 2 This service includes deposits, loans, transfers and cross-border remittances, cross-border e-commerce/supply chain financing, etc. 3 This service encompasses the business lines previously presented under “internet securities investment, account services, insurance agency services, and customer self-service banking outlet”. 4 This service includes lottery hardware sales, lottery offline distribution, as well as other integrated services. For more details, please visit www.agtech.com [1] Shareholders and potential investors should be aware that the Proposed Transfer of Listing is subject to, among others, the granting of relevant approval by the Stock Exchange. There is no assurance that approval and permission will be obtained from the Stock Exchange for the Proposed Transfer of Listing. Accordingly, the Proposed Transfer of Listing may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares. 18/06/2026 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-17 / 10:57 UTC+8 6月17日，隨著A股上市公司領益智造正式披露港股IPO招股書，舜宇光學科技旗下全資投資平台——舜宇資本有限公司（以下簡稱「舜宇資本」）首度公開亮相。舜宇資本作為領益智造港股上市的基石投資者之一，認購金額達2000萬美元，此舉標誌著舜宇光學科技正式開啟「產品價值+資本價值」雙輪驅動的戰略新階段。 作為舜宇資本成立後的首個標杆性投資項目，本次基石投資不僅是財務佈局，更是舜宇光學科技深化產業協同、構建資本朋友圈的關鍵落子。 據悉，舜宇資本是舜宇光學科技為落實新一輪五年戰略規劃，在香港設立的專注於資本運作的投資平台，不以短期財務回報為目標，而是聚焦Pre-IPO投資、基石投資、海外並購，以資本為紐帶，系統性構建舜宇在資本市場的「朋友圈」。 業內人士對舜宇資本的成立高度關注，認為該平台將成為舜宇光學科技掌控產業制高點、保障供應鏈安全、孵化新增長曲線的戰略支點。 2026-06-17 此新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 17/06/2026 / 10:57 UTC+8 On June 17, as A-share listed company, LINGYI iTECH (GUANGDONG) COMPANY (“LY iTECH”) formally disclosed its Hong Kong IPO prospectus, Sunny Optical Capital Limited (“Sunny Optical Capital”), the wholly‑owned investment platform of Sunny Optical Technology (Group) Company Limited, made its first public appearance. As one of the cornerstone investors in LY iTECH’s Hong Kong listing, Sunny Optical Capital subscribed US$20 million, and this move marks the official launch of Sunny Optical Technology’s new strategic phase of “dual‑drive” growth — combining product value and capital value. As the first landmark investment project since the establishment of Sunny Optical Capital, this cornerstone investment is not only a financial deployment, but also a critical move by Sunny Optical Technology to deepen industrial synergy and build its “circle of friends” in the capital market. It is understood that Sunny Optical Capital is an investment platform established by Sunny Optical Technology in Hong Kong to implement its new five‑year strategic plan, focusing on capital operations. It does not target short‑term financial returns, but instead concentrates on pre‑IPO investments, cornerstone investments, and overseas mergers and acquisitions, using capital as a link to systematically build Sunny Optical Technology’s “circle of friends” in the capital market. Industry professionals have paid close attention to the establishment of Sunny Optical Capital, believing that this platform will become a strategic fulcrum for Sunny Optical Technology to command the industrial high ground, ensure supply chain security, and incubate a new growth curve. 17/06/2026 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 17/06/2026 / 09:49 UTC+8 In the Hong Kong equity market, micro-cap stocks are routinely sidelined by institutional investors due to liquidity constraints and perceived single-business risks. However, Okura Holdings Limited (1655.HK)—a traditional operator of Japanese pachinko parlors in Nagasaki Prefecture—is quietly positioning itself at the confluence of global regulatory tailwinds. The company is orchestrating a textbook valuation re-rating, driven by the regulatory optionality within Japan's emerging casino sector. From a fundamental perspective, consensus opinion remains tethered to Okura’s mature core pachinko operations. Yet, value investors will recognize that this legacy portfolio anchors the enterprise with a resilient valuation floor. Following extensive consolidation within the Japanese gaming landscape, Okura has preserved a dominant regional footprint and robust cash generation in its home market. The stock currently trades at severely depressed multiples, with a trailing price-to-earnings (P/E) ratio around 2x and a price-to-book (P/B) ratio of approximately 0.3x. Amid macroeconomic volatility, this extreme valuation discount provides a formidable margin of safety, yielding a classic asymmetric risk-reward profile. The true catalyst, however, resides in the embedded option value of Japan’s secondary casino licenses (Integrated Resort, or IR concessions). Following the central government's approval of the MGM Resorts and Orix consortium in Osaka, Japan’s gaming ecosystem has entered a secular expansionary phase. Under current statutory frameworks, two additional casino licenses remain unallocated, and Tokyo is slated to reopen the competitive bidding window in 2027. Given that Nagasaki was a prime contender in the initial licensing tranche, local authorities are widely anticipated to mount a renewed bid. As the premier homegrown entertainment operator in Nagasaki, Okura commands deep-seated political networks and coveted commercial real estate assets, rendering it an indispensable local partner for multinational gaming concessionaires. Should the 2027 licensing momentum accelerate, Okura stands as a pure-play, micro-cap proxy primed for upward multiple expansion. While the upcoming casino bidding represents a compelling medium-term regulatory call option, management’s recent capital allocation strategy has delivered an immediate alpha generator. According to regulatory filings, Okura deployed its idle cash reserves into a pre-IPO vehicle targeting SpaceX(SPCX), securing Class A common stock at $126 per share just ahead of its Nasdaq debut. With SpaceX stock now surging past the $200 mark post-listing, Okura has locked in a staggering gain of over 58% on paper, capturing substantial balance sheet upside in a matter of days. While the absolute dollar amount is nominal relative to SpaceX's market capitalization, it represents a highly accretive asset appreciation for a company of Okura's scale. The transaction successfully breaks the valuation ceiling of a legacy entertainment stock, overlaying a premium global aerospace narrative onto its corporate profile without overshadowing its core gaming catalysts. Viewed holistically, Okura Holdings’ strategic posture reflects a calculated play on structural regulatory inflection points. The deeply discounted core business provides robust downside protection, while the 2027 Japan casino license reopening serves as a powerful catalyst to unlock balance sheet optimization. For sophisticated capital allocators hunting for deep value paired with asymmetric upside, this overlooked gaming play is emerging as a compelling dark horse. 17/06/2026 Dissemination of a Marketing Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-15 / 20:24 UTC+8 （香港，2026年6月15日）— 亞博科技控股有限公司（「亞博科技」或「本集團」，香港聯交所股份代號：8279）今日宣佈截至2026年3月31日止年度業績。 財務摘要 本集團截至2026年3月31日止年度的收益為約760,500,000港元（截至2025年3月31日止年度：約615,000,000港元），較截至2025年3月31日止年度增加約23.7%。截至2026年3月31日止年度，收益貢獻主要來自以下業務： 數字支付及相關業務（包括商業賦能及本地消費者服務業務及支付相關硬件銷售及租賃收入）：截至2026年3月31日止年度，收益整體增加約16,600,000港元至約323,800,000港元，主要歸因於澳門入境遊客增長及受惠於「2025年社區消費大獎賞」等促銷活動，以數字方式支付的本地消費增加，推動交易支付金額增加。 此外，截至2026年3月31日止年度，商業賦能及本地消費者服務業務收益增加約85.2%至約27,700,000港元，主要因提供予本地消費者及商戶的持續戰略舉措所推動。 實體與數字銀行業務：截至2026年3月31日止年度，收益整體增加約157,700,000港元至約225,500,000港元，主要因(i)螞蟻銀行（澳門）的財務報表於整個年度而截至2025年3月31日止年度僅約七個月（本集團於2024年9月2日完成收購本集團於螞蟻銀行（澳門）的控股權後）併入本集團；(ii)本集團持續創新令客戶基礎及客戶存款顯著增長所致。 彩票業務：收益整體減少約28,700,000港元至截至2026年3月31日止年度約211,200,000港元，主要因彩票硬件銷售收益因彩票硬件中標及交付減少而減少約35,500,000港元，並部分被提供透過實體渠道代銷彩票服務所得收益增加約6,800,000港元所抵銷。 截至2026年3月31日止年度，年度虧損為約54,200,000港元（截至2025年3月31日止年度：約98,600,000港元）。年度虧損整體減少乃主要歸因於：(i)截至2026年3月31日止年度未就本集團原先向其擁有45%權益的印度合資公司First Games Technology Private Limited（「合資公司」）提供並已被該合資公司悉數動用的最高金額為1,319,400,000盧比（相等於約137,300,000港元）的可轉換定期貸款融資確認公平值變動，而截至2025年3月31日止年度則為公平值虧損約70,900,000港元。截至2026年3月31日止年度，本集團與合資公司訂立雙方協議終止融資，且本集團確認終止確認收益約3,500,000港元；及(ii)融資收入減少約14,000,000港元至約30,300,000港元（截至2025年3月31日止年度：約44,300,000港元），主要歸因於截至2026年3月31日止年度的市場利率較2025年同期有所減少。 業務回顧 報告期內，集團高增速業務占比持續提升，收入結構進一步優化，核心經營指標穩步改善，標誌著公司正加速從「彩票+支付」服務商向「綜合金融科技平台」轉型。目前，集團核心業務板塊協同發力，在鞏固數字支付領先優勢的同時，銀行業務進入高速增長階段，黃金及貴金屬交易創新技術服務則打開新的成長空間，整體戰略轉型成效初步顯現。 本集團的金融科技業務逐步演變成一個數字生態圖（如上圖所示） 一、綜合金融業務 依託澳門通與螞蟻銀行（澳門）的深度協同，本集團正全面構建覆蓋高頻支付與綜合金融服務的金融科技生態圈。 1. 數字支付業務 本集團的數字支付業務主要通過澳門通開展。澳門通作為澳門領先的數字支付服務提供商，主要開展澳門通卡、MPay及商戶收單等業務。 澳門通卡是澳門居民及訪澳旅客廣泛使用的非接觸式支付卡，目前累計發卡量超過600萬張，全面覆蓋澳門本地公共交通及超過3萬個消費終端。於報告期內，澳門通持續深化區域互聯互通戰略，先後與珠海、武漢等城市合作推出「珠澳聯名公交卡」「武澳一卡通聯名卡」等產品。同時，通過推出NBA中國賽聯名卡、卡皮巴拉澳門通MINI卡等產品，突破傳統交通卡定位，進一步推動品牌年輕化發展。自2025年9月26日起，澳門通卡新增內地支付寶充值服務，進一步優化跨境支付服務，提升內地遊客在澳出行便利。 MPay是澳門居民最常用的電子錢包之一，註冊用戶約為173萬，目前已發展成為涵蓋餐飲、交通、旅遊、娛樂、線上線下購物、金融服務以及跨境服務與支付等豐富場景的Super APP。在本地生態建設方面，MPay持續深化數字服務體驗，創新推出「碰一下」便捷支付功能，並上線「高德打車」小程序。同時，其跨境業務展現出較強增長動能，報告期內，跨境支付交易筆數與交易總額同比分別增長約43%和44%。目前，MPay跨境支付網絡已覆蓋全球約60個國家和地區；為便利澳門居民北上消費與出行，平台不斷豐富「跨境專區」生態，現已接入包括高德打車、美團點餐、廣州地鐵乘車碼在內的近90個內地熱門小程序。 澳門通亦是澳門領先的收單機構之一，支持10餘個境外國家和地區電子錢包在澳使用。報告期內澳門通在澳門率先引入了支付寶「碰一下」及MPay「碰一下」等創新支付方式，並攜手澳門金沙度假區等本地商業夥伴深化場景合作。截至2026年3月31日，「碰一下」支付服務已覆蓋澳門超過8000家商戶網點。 2. 實體與數字銀行業務 本集團的銀行業務由螞蟻銀行（澳門）開展。螞蟻銀行（澳門）是澳門本地一間擁有全牌照的實體與數字銀行，為個人及中小企業用戶提供便捷開戶、支付消費、全球匯款、儲蓄理財（包括保險代理）及信貸等綜合金融服務。 於報告期內，我行持續完善存、貸、匯、兌、投的全產品服務體系，並穩步推進線下服務網絡。2025年10月，本行首個自助服務網點正式投入運營，未來還將建設更多財富管理中心，逐步形成「線上數字化+線下服務網絡」協同發展的綜合銀行服務模式。此外，我們還設立保險線上繳費專區，及與滙豐保險產品達成代銷合作，進一步豐富產品矩陣。同時，在客戶經營方面，本行聚焦年輕客群，通過數字化運營與線下服務場景融合，相較傳統銀行打造更具科技感和差異化的客戶服務體驗。於報告期內，本行實現客戶基礎及資金規模雙增長，個人客戶總數同比增長約76%，存款總額同比增長約235%。 二、商業賦能及本地消費者服務業務 基於MPay龐大的用戶基礎及支付流量，以及mCoin、mPass平台協同優勢，集團持續推動線上流量向線下商業價值轉化，賦能本地商業發展。 mPass依託MPay支付生態協同優勢，為澳門居民及遊客提供涵蓋餐飲、購物、娛樂、活動及高端定制服務的綜合生活與旅遊服務平台。於報告期內，與澳門經科局、大麥網聯合推出「演唱會+社區消費優惠」活動，引導演唱會客流至澳門新口岸填海區等社區消費場景；同時，還聯動MPay支持政府及商業促消費項目，如「全運聚力· 社區消費大獎賞」、「與POP MART漫遊澳門」等，有效促進用戶消費活躍度提升。此外，於報告期內，亦支持了超過130場演出及賽事活動在澳門的落地。 mCoin激活積分經濟：作為MPay的專屬積分權益平台，mCoin於報告期內新上線轉贈功能。截至2026年3月31日，累計轉贈規模達約10億mCoin積分；同時推出「抵到爆」積分兌換計劃，聯合優質商戶提供專屬商品等優惠活動，實現用戶實惠與商戶引流的雙向促進。 於報告期內，集團持續深化與產品夥伴合作，以數字科技全面賦能本地商業升級與智慧城市建設。除了與支付寶、金沙中國合作於澳門金沙度假區率先引入「碰一下」支付服務外，我們還與高德地圖合作推出「清涼出行節」「高德掃街榜-地道澳門味榜單」及「煙火澳門支持計劃」，全方位支持澳門本地商家經營，助力中小商戶數字化轉型與服務能力升級，亦促進社區經濟發展。此外，我們還陸續與華為服務（香港）有限公司、中國電信（澳門）有限公司、中國對外文化集團有限公司、大麥娛樂、「澳門銀河™」綜合度假城等達成戰略合作，共同探索數字服務創新、智慧城市建設及文化內容發展等領域合作機遇。 三、黃金及貴金屬交易創新技術服務 作為集團創新金融佈局，亞博科技將為港金所及其市場參與者設計、開發並維護一個安全可靠的電子交易、清算及結算平台。該平台將集現貨、期貨、數字黃金、B2C交易、清結算中心、場外OTC交易、會員管理與統一風控體系於一體，包括離岸及在岸人民幣，並具備多幣種計價與結算能力、多語言支援和開放相容的架構設計，旨在提升市場效率、連接全球投資者，助力香港強化其國際黃金樞紐的地位。 四、彩票業務 彩票業務保持穩健發展。亞博科技作為國內領先的彩票終端投注設備供應商之一，於報告期內，贏得了12項彩票硬件招標，向湖北、海南、山東、天津、貴州、江蘇、陝西、廣東、福建、重慶等省份體彩中心提供彩票終端機。 業務前景 本集團致力於成為全球領先的綜合性金融科技集團，以綜合金融業務、商業賦能及本地消費者服務業務以及黃金及貴金屬交易創新技術服務為核心構建全方位數字生態圈，打造現代金融服務新範式。 本集團將持續強化「支付+金融+技術」基礎設施，通過提供實體與數字銀行、電子錢包、收單、澳門通卡及多用途數字支付系統等多元服務，不斷深化服務場景建設，提升本地居民與遊客的支付體驗，推動澳門的移動支付和普惠金融的普及，並為智慧城市轉型作出貢獻。 依託與阿里巴巴集團及螞蟻集團的生態合作，並藉助Alipay+的全球連接優勢，本集團將進一步推動支持更多境外國家及地區的電子支付工具，便利來澳旅客消費，實現跨境支付便利化。同時，本集團將充分發揮自身在內容與渠道上的優勢，為澳門商家提供更多線上曝光機會，並為商戶提供數字化升級解決方案，助力其實現數字化轉型，推動澳門本地經濟發展，服務「世界旅遊休閒中心」的建設。在此基礎上，本集團將以支付與綜合金融業務連接場景與生態資源，通過內部業務協同，持續拓展多元化業務佈局。我們亦將進一步探索數字支付生態系統、電子商務、數字媒體娛樂以及文化娛樂市場的更多商業化機會，不斷豐富數字生態圈的價值內涵。 面向Web3.0時代，本集團前瞻性地佈局創新金融賽道，目前正加速探索黃金及貴金屬交易與前沿科技的深度融合，著力搭建具備國際競爭力的創新交易平台。展望未來，我們將持續深化佈局，通過技術驅動與生態共建，不斷拓寬貴金屬交易技術的應用邊界，為粵港澳大灣區乃至更廣泛區域的金融市場突破發展注入新的活力與動力。 啟始澳門，通路八方，連接世界。本集團將持續投入資源以改善其技術基礎設施，同時圍繞用戶需求，不斷深化服務場景，拓展全球金融服務版圖，探索更多業務創新機會，繼續踐行致力為股東帶來長期可持續增長的承諾。 -完- 關於亞博科技控股有限公司 亞博科技是阿里巴巴集團成員公司，於百慕達註冊成立，其股份在GEM上市（股份代號：8279），並獲納入MSCI全球微型股指數。作為一家綜合性金融科技集團，亞博科技的核心業務大致分為四大類： (1) 綜合金融業務： (i) 數字支付業務： (a) 澳門通卡 (b) MPay (c) 商戶收單服務1 (ii) 實體與數字銀行業務： (a) 個人和中小企數字銀行服務2 (b) 財富管理服務3 (2) 商業賦能及本地消費者服務業務： 生活服務、文娛服務、為商戶提供營銷技術服務及電商平台 (3) 黃金及貴金屬交易創新技術服務 (4) 彩票業務4 1 該業務亦包含原於「支付相關硬件供應」項下呈列的業務範疇。 2 該業務包含存款、貸款、轉帳及跨境匯款、跨境電商/供應鏈融資等業務。 3 該業務包含原於「互聯網證券投資、帳戶服務、保險代理服務及客戶自助網點銀行服務」項下呈列的業務範疇。 4 該業務包含彩票硬件銷售、透過實體渠道代銷彩票及其他整合服務。 詳情請瀏覽 www.agtech.com 2026-06-15 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 15/06/2026 / 20:24 UTC+8 （Hong Kong, June 15, 2026）— AGTech Holdings Limited (“AGTech”or“the Group”, HKEX Stock Code: 8279) today announced its final results for the year ended march 31, 2026. FINANCIAL HIGHLIGHTS Revenue of the Group for the year ended March 31, 2026 amounted to approximately HK$760.5 million (Year ended March 31, 2025: approximately HK$615.0 million), representing an increase of approximately 23.7% compared to the year ended March 31, 2025. For the year ended March 31, 2026, revenue contributions were mainly derived from the following businesses: Digital payment and related businesses (including commerce enablement and local consumer services and payment-related hardware sales and lease income) There was an overall increase in revenue by approximately HK$16.6 million to approximately HK$323.8 million for the year ended March 31, 2026, mainly due to the increase in transaction payment volume (TPV) driven by the rise in inbound tourists in Macau and increase in local consumption through digital payment benefiting from the consumption promotion campaign such as the “Community Consumption Grand Prize 2025”. Furthermore, the revenue from commerce enablement and local consumer services increased by approximately 85.2% to approximately HK$27.7 million for the year ended March 31, 2026, mainly driven by its continuous strategic initiatives provided to the local consumers and merchants. Full-scale banking business There was an overall increase in revenue by approximately HK$157.7 million to approximately HK$225.5 million for the year ended March 31, 2026, mainly due to (i) the consolidation of financial statements of ABM (Ant Bank (Macao) Limited) into those of the Group for the entire year, compared with only about seven months for the year ended March 31, 2025 following the completion of the Group’s acquisition of a controlling stake in ABM on September 2, 2024; (ii) the Group’s continuous innovations have led to a significant growth in both customer base and customer deposits. Lottery business There was an overall decrease in revenue by approximately HK$28.7 million to approximately HK$211.2 million for the year ended March 31, 2026, mainly due to the decrease in revenue from sales of lottery hardware by approximately HK$35.5 million as a result of the decrease in lottery hardware tenders awards and deliveries and partially offset by the increase in revenue from the provision of lottery offline distribution services by approximately HK$6.8 million. The loss for the year ended March 31, 2026 was approximately HK$54.2 million (for the year ended March 31, 2025: approximately HK$98.6 million). The overall decrease in loss for the year is primarily attributable to: (i) no fair value changes were recognized for the year ended March 31, 2026 on the convertible term loan facilities in the maximum amount of INR1,319.4 million (equivalent to approximately HK$137.3 million) previously provided by the Group to, and fully utilized by, its 45%-owned joint venture company in India, First Games Technology Private Limited (“JV”), as compared to a fair value loss of approximately HK$70.9 million for the year ended March 31, 2025. During the year ended March 31, 2026, the Group has entered into a mutual agreement with the JV for the termination of the Facilities and a gain on derecognition of approximately HK$3.5 million was recognized by the Group; and (ii) the decrease in finance income by approximately HK$14.0 million to approximately HK$30.3 million (for the year ended March 31, 2025: approximately HK$44.3 million) mainly due to the decrease in market interest rates for the year ended March 31, 2026 as compared to the corresponding period in 2025. BUSINESS REVIEW During the reporting period, the proportion of the Group's high-growth businesses continued to rise, optimizing the revenue structure and driving steady improvement across key operating indicators. These trends signal an accelerated shift from a "lottery + payment" provider to an “integrated fintech platform”. Core business segments are now working in synergy: alongside our leading position in digital payments, our full-scale banking services are growing rapidly, while innovative technology services for the gold and precious metals trading have opened up new growth horizons. Overall, the initial results of the strategic transformation are beginning to materialize. The Group’s fintech businesses have evolved into a digital ecosystem (as outlined in the diagram above). Full-scale Financial Services Leveraging the deep synergy between Macau Pass and ABM, the Group is comprehensively building a fintech ecosystem that encompasses both high-frequency payments and full-scale financial services. Digital Payment Services The Group's digital payment business is primarily conducted through Macau Pass, which is one of the leading digital payment service providers in Macau, principally engaged in mCard, MPay and merchants acquiring services. mCard is a contactless payment card widely used by Macau residents and visitors. There are currently over 6.0 million mCards in issuance, supporting local public transportation and over 30,000 consumption points across Macau. During the reporting period, mCard continuously deepened its regional connectivity strategies, in collaboration with cities across the Chinese Mainland, including Zhuhai and Wuhan, we launched the “Zhuhai-Macao Public Transport Card”,“Wuhan-Macau Intercity Card” , etc. At the same time, we subsequently launched a series of creative products, including the NBA China Games mCard, the Capybara MINI mCard, moving beyond the traditional transit card role and further promoting brand rejuvenation. The cross-border payment service was also optimized. With the addition of a top-up service option for Alipay users on September 26, 2025, it has significantly enhanced the convenience of payment and travel for tourists from Chinese Mainland in Macau. MPay is one of the most widely used e-wallets among Macau residents，with approximately 1.73 million registered users. It has become a Super App that covers dining, transportation, tourism, entertainment, online and offline shopping, finance and cross-border services and payments. On the local ecosystem front, MPay has continuously deepened its local digital ecosystem by launching the MPay Tap! Function and extending the“Amap Ride-Hailing” mini-app to the local Macau market. Meanwhile, its cross-border payment ecosystem has shown strong growth momentum. During the reporting period, the number of cross-border payment transactions and the total transaction payment volume increased by approximately 43% and approximately 44% year-on-year, respectively. In terms of international payment networks, MPay now supports users in about 60 countries and region. To facilitate northbound consumption and travel by Macau residents, it has been continuously enriching its "Cross-Border Zone" ecosystem, which now integrates approximately 90 popular mini-apps in the Chinese Mainland, including Amap Ride-Hailing, Meituan Takeout, and transit QR code of Guangzhou Metro. We are also one of the leading acquirers in Macau. Our acquiring services support travellers from over 10 overseas countries and region to use their home country/region’s e-wallets in Macau. During the reporting period, Macau Pass pioneered the introduction of innovative payment solutions exemplified by Alipay Tap! and MPay Tap! Features, and deepened scenario-based cooperation with local business partners including Sands China. As of March 31, 2026, Alipay’s innovative payment method Alipay Tap! has covered over 8,000 merchant stores across Macau. Full-scale Banking Services The Group's banking business is conducted by ABM (the “Bank”). ABM is a local full-scale bank in Macau holding a full banking licensce, providing comprehensive financial services including convenient account opening, payment and spending, global remittance, savings and wealth management (including insurance agency), and credit services to individuals and SMEs users. During the reporting period, the Bank continues to improve the full range of product services system including deposits, loans, remittances, currency exchange, and investments. The Bank also advanced its offline expansion strategy, opening its first self-service outlet in October 2025 and will consider setting up other wealth management centers in the future, gradually forming a comprehensive banking service model that integrates online digital capabilities with an offline service network. In addition, we established an online insurance payment zone and reached an agency cooperation agreement with HSBC insurance products, further expanding the product portfolio. In terms of customer management, the bank also focuses on youngster and endeavors to reach users with differentiated services through online operations and offline outlets, forming a distinct customer service advantages over conventional banks. During the reporting period, the Bank achieved growth in both customer base and fund size, with the total number of individual customers increasing by approximately 76% year-on-year and total deposits growing by approximately 235%. Commerce Enablement and Local Consumer Services Leveraging MPay’s large user base and payment traffic, together with the synergistic advantages of the mCoin and mPass platforms, the Group continues to convert online traffic into offline commercial value,empowering local business development. Leveraging the synergies of the MPay payment ecosystem, mPass provides Macau residents and tourists with a comprehensive lifestyle and travel service platform offering a wide range of services across dining, shopping, entertainment, events and high-end customised travel experiences. During the reporting period, mPass in collaboration with the Macau Economic and Technological Development Bureau and Damai, launched the “Concert + Community Consumption Benefits” campaign, effectively directing concert-goers to communities such as the Zona de Aterros do Porto Exterior (“ZAPE”,新口岸填海區). Meanwhile, it collaborated with MPay to support government and commercial initiatives to boost consumption, such as the “National Games Boost • Community Consumption Grand Prize”, and the “POP MART Macao Citywalk” (與POP MART漫游澳門), effectively increasing users’ spending activity. Additionally, during the reporting period, mPass has also supported over 130 performances and events in Macau. mCoin activates the points economy: mCoin is MPay’s exclusive points and benefits platform. During the reporting period, the mCoin platform has newly launched an mCoin gift feature. As of March 31, 2026, the cumulative volume of mCoins transferred via the gift function reached approximately 1 billion mCoins. The platform also launched the “Value Buy” (抵到爆) mCoins redemption program, collaborating with high-quality merchants to provide exclusive products, thereby achieving a mutually beneficial promotion of advantages for users and increased traffic for merchants. During the reporting period, the Group continued to deepen partnerships with product partners, leveraging digital technology to empower local business upgrades and the development of smart cities. In addition to collaborating with Alipay and Sands China to launch the Alipay Tap! Service at Sands Resorts Macao, we also collaborated with Amap to launch the “Cool Travel Festival” (清涼出行節), the “Amap Street Stars -Macao Authentic Delicacies Ranking” and the “Macao City Life Support Program”. These initiatives not only provided comprehensive support for Macau’s local merchants and empower local small and medium-sized merchants in their digital transformation and service capability upgrade, but also contributed to the growth of community economies. Furthermore, we successively established strategic cooperation with Huawei Services (Hong Kong) Limited, China Telecom (Macau) Limited, China Arts and Entertainment Group Ltd., Damai Entertainment and the Galaxy Macau™ integrated resort. These collaborations aim to explore opportunities in areas such as digital service innovation, smart city development, and cultural content growth. Innovative Technology Services for the Gold and Precious Metals Trading As part of the Group’s innovative financial strategy, the Group will design, develop, and maintain a secure and reliable electronic trading, clearing and settlement platform for HKGX and its market participants. The platform will integrate spot, futures, digital gold, B2C transactions, clearing and settlement center, over-the-counter (OTC) trading, membership management and a unified risk control system. It will support both offshore and onshore Renminbi, featuring multi-currency pricing and settlement capabilities, multilingual support, and an open and compatible architectural design. The platform aims to enhance market efficiency, connect global investors, and help strengthen Hong Kong’s position as an international gold hub. Lottery Services The lottery business maintained steady growth. The Group is one of the leading suppliers of lottery terminals in China. During the reporting period, the Group won 12 lottery hardware tenders to supply lottery terminals to the Sports Lottery Administration Centers in a number of provinces and municipalities, including Hubei, Hainan, Shandong, Tianjin, Guizhou, Jiangsu, Shaanxi, Guangdong, Fujian and Chongqing. BUSINESS OUTLOOK The Group is dedicated to becoming a leading global comprehensive financial technology group. With full-scale financial services, commerce enablement and local consumer services, and innovative technology services for the gold and precious metals trading as its core, the Group aims to build a comprehensive digital ecosystem and create a new paradigm for modern financial services. The Group will continue to strengthen its “payment + finance + technology” infrastructure. By offering full-scale banking services, e-wallet, acquiring services, mCard, multipurpose digital payment system and other services, we will continuously deepen the development of service scenarios to enhance the payment experience for local residents and tourists, while striving to promote mobile payment and inclusive finance in Macau, and contribute to its smart city transformation. Leveraging its ecosystem collaboration with Alibaba Group and Ant Group, and capitalizing on the global connectivity advantages of Alipay+, the Group will further provide support for more electronic payment tools from overseas countries and regions to facilitate the consumption of visitors to Macau, and achieve cross-border payment facilitation. Additionally, the Group will fully leverage its strengths in content and channels to provide Macau merchants with increased online exposure and digital upgrade solutions, empowering them to achieve digital transformation, thereby driving Macau’s local economic development and supporting the construction of a “World Centre of Tourism and Leisure”. On this basis, the Group will connect scenarios and resources of the ecosystem with payment plus full-scale financial services, leverage internal business synergies to continue to expand its diversified business portfolio. We will also further explore additional commercialization opportunities across the digital payment ecosystem, e-commerce, digital media and entertainment, and cultural entertainment markets, continuously enriching the value proposition of our digital ecosystem. Looking ahead to the Web3.0 era, the Group has been actively expanding into innovative finance. We are currently accelerating the deep integration of gold and precious metals trading with cutting-edge technologies, striving to build an innovative trading platform with international competitiveness. Moving forward, we will continue to deepen our strategic layout. By leveraging technology-driven initiatives and ecosystem co-creation, we aim to constantly expand the application boundaries of precious metals trading technology, injecting new vitality and momentum into the financial market development of the Guangdong-Hong Kong-Macao Greater Bay Area and beyond. With roots in Macau and sights set on the global stage, the Group will continue to invest resources to improve its technological infrastructure. Focused on user needs, we will continuously deepen service scenarios, expand our global financial service footprint, seek innovative business opportunities and continue delivering on our commitment to provide long-term sustainable growth for the shareholders. -End- ABOUT THE GROUP AGTech, as a member of the Alibaba Group, was incorporated in Bermuda and its Shares are listed on GEM (Stock Code: 8279). The Company is included as a constituent stock in the MSCI World Micro Cap Index. As a comprehensive financial technology group, AGTech’s core businesses are broadly divided into four principal categories: (1) Full-scale financial services: (i) Digital payment services: (a) mCard (b) MPay (c) Merchants acquiring services 1 (ii) Full-scale banking services: (a) Digital banking services for individuals and SMEs 2 (b) Wealth management services 3 (2) Commerce enablement and local consumer services: lifestyle, culture and entertainment, marketing technical services for merchants and e-commerce platform (3) Innovative technology services for the gold and precious metals trading (4) Lottery services 4 1 This service also includes the business line previously presented under “payment‑related hardware supply”. 2 This service includes deposits, loans, transfers and cross-border remittances, cross-border e-commerce/supply chain financing, etc. 3 This service encompasses the business lines previously presented under “internet securities investment, account services, insurance agency services, and customer self-service banking outlet”. 4 This service includes lottery hardware sales, lottery offline distribution, as well as other integrated services. For more details, please visit www.agtech.com 15/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS Newswire / 09/06/2026 / 16:00 UTC+8 (9 June 2026, Hong Kong) Waton Financial Limited Unveils MoTA: An AI-Native Investment Team Operating System and Agent Marketplace That Lets Anyone Build, Manage, and Command Their Own Professional Investment Research Team Waton Financial Limited today unveiled MoTA (Manager of Trading Agents), an AI-native investment team operating system and Agent marketplace that redefines what AI can do for investors. MoTA is not a stock-picking chatbot or a black-box trading bot. It is a platform designed to let users build, manage, and command their own team of specialized AI Agents across the full investment workflow — from portfolio definition to trade execution. The Problem Professional investment research has always required a team: factor researchers, fundamental analysts, technical analysts, risk managers, portfolio constructors, and trade execution officers. Each role demands specialized talent and expensive infrastructure. For individual investors and small teams, assembling such a capability has been cost-prohibitive — until now. The Solution MoTA transforms the user from a passive consumer of AI signals into an active leader of an AI-powered investment team. Its four integrated modules work together to deliver a seamless, end-to-end experience. First, Talents — the Agent Marketplace. Users browse, compare, and hire specialized AI Agents by role. Each Agent is purpose-built for a specific investment function — fundamental analysis, technical analysis, risk management, trade execution, and more. Agents can be swapped and composed as strategies evolve. Second, Team — composing your investment team. Users assemble multiple Agents into a structured team. Analysts feed research inputs, the Portfolio Manager evaluates and writes memos, the Risk Manager reviews exposure, and the Trader validates routing. The human user retains final sign-off authority at every stage. Third, Portfolio — the portfolio cockpit. A real-time overview of holdings, assets, P&L, risk, and exposure. Users see exactly what is moving across positions, where risk sits, and where returns originate — all in one unified view. Fourth, Decision — the Decision Center. Every Agent-generated suggestion surfaces in the Decision Center with full context: source Agent, signal, reasoning, and current status. Users can click into the full workflow or execution path, compare competing analyses, and manage an actionable queue of decisions. Every recommendation is structured, traceable, and auditable. These four modules connect in a continuous workflow: Portfolio to Decision to Team to Trade. Why MoTA Is Different Traditional AI investing tools offer a single AI chat box, scattered research answers, black-box signals, no role separation, and AI value that is hard to measure. Reviews are tied to AI silos. MoTA provides a multi-Agent investment team, a connected Portfolio-to-Trade workflow, an auditable Decision Center, dedicated Analyst and PM and Risk and Trader roles in coordination, unified metrics such as ROI and win rate and cost per run and override rate, and a unified path for portfolio, decisions, Agents, and trades. The Vision Behind MoTA Waton Financial Limited's mission with MoTA is clear: to make professional-grade multi-agent investing tools more accessible, more transparent, and more user-controlled. MoTA does not replace human judgment — it amplifies it. The platform frees users from the burden of being a full-stack investment expert and elevates them to a higher role: the builder, manager, and decision-maker of their own AI investment team. As AI moves from content generation into workflow execution, investing — inherently a multi-role, multi-step, multi-constraint process — is a natural fit for this transformation. MoTA is designed to bridge the gap between what AI can do and what the investment workflow actually needs. About MoTA MoTA (Manager of Trading Agents) is Waton Financial Limited's flagship AI-native investment team operating system and marketplace for specialized investing Agents. It enables users to create fully customizable investment teams, assign specialized AI Agents to each role, and receive structured, traceable, and auditable investment suggestions across the entire Portfolio-to-Trade workflow. About Waton Financial Limited Waton Financial Limited is a publicly listed financial services and technology company that designs, owns, and operates the MoTA platform. Waton is committed to building AI-native infrastructure for investment teams and making professional-grade multi-agent investing tools accessible to a broader audience. Welcome to MoTA. Welcome to the new era of investing. Media Contact Email: ir@watonfinancial.com Website: https://wtf.us Explore MoTA: https://mota.ai Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those expressed or implied. This is not investment advice. Past performance does not guarantee future results. 09/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com View original content: EQS News

EQS via SeaPRwire.com / 2026-06-12 / 15:02 UTC+8 ASCO 2026公佈的多項臨床數據進一步驗證了CS2009的三靶點協同機制，並支持其作為新一代腫瘤免疫治療（I/O）骨架藥物的重要開發潛力。 一、三抗設計邏輯與差異化優勢 1、相較VEGF聯合PD-1具有更大的長期生存獲益潛力，同時CTLA-4相關毒性低、耐受性良好 CS2009通過PD-1、VEGF和CTLA-4三靶點協同設計，旨在同時恢復T細胞效應功能、改善腫瘤微環境並增強T細胞初始啟動，從而實現更深、更持久的抗腫瘤免疫應答。 • CTLA-4結構域差異化設計：通過使外周CTLA-4單陽性T細胞免於過度啟動，降低系統性免疫毒性，結合VEGF介導的腫瘤組織富集效應，在保留CTLA-4免疫啟動作用的同時顯著改善耐受性。臨床數據顯示，CS2009的CTLA-4相關毒性明顯低於傳統CTLA-4抗體治療方案，免疫相關不良事件（irAE）發生率降至與PD-1單抗和雙抗接近的水準。 • 持續給藥優勢：傳統CTLA-4抗體通常僅能耐受兩至三次給藥，而CS2009可持續給藥，從而更充分地發揮CTLA-4結構域的作用。該結構域不僅可以啟動與增強對已存在的腫瘤抗原的免疫反應，還能針對後續發生的新腫瘤抗原啟動新的T細胞克隆，持續擴增抗腫瘤T細胞庫。結合CS2009良好的耐受性，這一機制有望帶來更持久的免疫應答，支持長期臨床獲益和延長患者生存。 • 藥效學驗證：觀察到ICOS（T細胞活化標記物）呈劑量依賴性上升，作為CTLA-4通路活化後公認的藥效學標記物，ICOS上調提示CS2009能夠持續促進T細胞初始啟動與克隆擴增，驗證了其CTLA-4結構域的生物學活性，並為長期抗腫瘤免疫應答提供生物學依據。 （行業挑戰： 歷史上多數抗VEGF聯合PD-(L)1方案主要改善PFS，而OS獲益存在較大不確定性。CS2009通過引入CTLA-4機制，力圖突破這一局限。） 2、低VEGF相關毒性，支持更充分的治療暴露和持續獲益 藥效學數據顯示： • 給藥後循環VEGF水準持續下降，經過147天隨訪仍未觀察到明顯反彈趨勢。 這一現象與傳統抗VEGF抗體或PD-1/VEGF雙抗觀察到的結果存在差異，可能與CS2009在腫瘤微環境中富集並通過CTLA-4介導內吞清除VEGF-抗體複合物有關，從而減少VEGF及其抗體結合複合物回流至外周循環，有助於降低高血壓、蛋白尿等VEGF相關系統性毒性。 臨床數據顯示： • VEGF相關≥3級治療相關不良事件（TRAE）發生率僅為5.1%，明顯低於部分已報導的VEGF雙抗方案。 （行業挑戰：VEGF既是重要療效驅動因素，也是聯合治療中主要毒性來源之一；高齡及高危患者毒性風險更高，可能影響生存獲益。如何平衡療效與耐受性，是VEGF賽道長期未解決的問題。） 3、冷腫瘤中持續觀察到積極信號，體現CTLA-4結構域潛在價值、驗證三靶點協同機制 在多個傳統I/O敏感性較低的瘤種中，包括：免疫治療耐藥非小細胞肺癌（NSCLC）、pMMR/MSS轉移性結直腸癌（mCRC）、軟組織肉瘤（STS）、非透明細胞腎癌（nccRCC），均觀察到積極的臨床活性。這一結果提示，CS2009通過同時阻斷PD-1和CTLA-4，並結合VEGF機制，能夠增強T細胞初始啟動、擴展T細胞克隆譜、促進長期免疫記憶和持續抗腫瘤作用，同時改善腫瘤微環境中T細胞浸潤，使免疫應答覆蓋更多原本對I/O治療不敏感的腫瘤。 多個冷腫瘤中的一致性療效信號進一步支持，CS2009通過PD-1、CTLA-4和VEGF三靶點的協同作用，有能力重塑免疫抑制微環境，擴大免疫獲益人群，並顯示出突破傳統PD-1單抗及PD-1/VEGF雙抗療效邊界的潛力。 （行業挑戰： 對於I/O不敏感冷腫瘤，目前仍缺乏真正有效的免疫治療方案，PD-1聯合CTLA-4仍是國際公認的重要突破方向之一。） 4、鱗癌與非鱗癌均觀察到一致獲益，體現廣泛適用性 • 在NSCLC多個治療場景中：鱗癌與非鱗癌患者均觀察到相近緩解率。 CS2009目前顯示出跨組織學亞型的一致獲益趨勢，提示其機制可能不依賴於特定病理類型，有望覆蓋更廣泛的NSCLC患者人群，並提高未來全球註冊試驗成功的確定性。 （行業挑戰：鱗癌與非鱗癌之間往往存在明顯的療效差異，限制了部分產品的適應症拓展和商業化空間。） 二、安全性優勢明確，VEGF毒性顯著低於雙抗 截至目前I期臨床數據顯示，在混合瘤種中（N=118）： • ≥3級TRAE發生率：24.6%； • ≥3級irAE發生率：12.7%； • VEGF相關≥3級TRAE發生率：5.1%。 聚焦NSCLC後線隊列（n=57）的安全性： • ≥3級TRAE發生率：19.3%； • ≥3級irAE發生率：12.3%； • VEGF相關≥3級TRAE發生率：5.3%； 與I期多線經治混合瘤種人群整體的安全譜一致。 整體上： • CTLA-4相關毒性得到很有效的控制； • 未觀察到非預期的安全性信號； • 整體安全性特徵接近PD-1/VEGF雙抗水準，VEGF毒性顯著低於雙抗。 這一安全性表現為後續長期給藥和全球註冊開發提供了重要基礎。 三、療效數據：冷腫瘤領域展現差異化價值 CS2009在多種難治性冷腫瘤中顯示出有意義的臨床活性，凸顯其差異化的機制 1、結直腸癌後線單藥（pMMR/MSS mCRC）： • 入組患者均為經治的難治性CRC，包括BRAF突變型和右側結直腸癌； • CS2009單藥：ORR 25%，DCR 87.5%。 考慮到傳統後線治療ORR通常僅為個位數水準，該結果已展現出具有臨床意義的抗腫瘤活性。 更重要的是，療效信號出現在典型I/O冷腫瘤人群中，進一步支持CTLA-4結構域帶來的潛在差異化價值。 2、一線聯合XELOX治療（pMMR/MSS mCRC）： • 研究未篩選左右半結腸、分子亞型或肝轉移狀態，入組人群更接近真實世界臨床實踐。 • 截至目前：6例患者均出現腫瘤縮小，3例首次療效評估即達到PR • ORR 66.7%，DCR 100%。 雖然目前樣本量仍然較小，但已觀察到高度一致的早期療效信號，為後續全球註冊開發提供了積極支持。 公司計畫繼續擴大樣本量至40例，以形成更完整的概念驗證（POC）數據包，用於後續與包括美國食品藥品監督管理局（FDA）和中國國家藥品監督管理局（NMPA）在內的全球監管溝通III期全球註冊臨床試驗方案。 3、其他冷腫瘤 • 軟組織肉瘤（STS）後線單藥：ORR 33.3%，DCR 66.7%； • 非透明細胞腎細胞癌（nccRCC）後線單藥：ORR 33.3%，DCR 100%； • 患者療效持久：I期首位患者（澳洲女性）12個月腫瘤持續縮小超40%。 四、NSCLC：多維度數據支持全球註冊開發 維度一：後線NSCLC單藥（IO/化療/ADC/雙抗經治） • 30mg/kg劑量組整體ORR 24%（鱗癌25%，非鱗癌23.1%，獲益一致），DCR 60%； • 二線NSCLC（30mg/kg，IO+化療經治）數據進一步提升：ORR 30.8%，DCR 84.6%。 在此類經PD-(L)1治療後患者中，目前標準治療ORR通常較低，因此CS2009已展現出具有競爭力的單藥活性。 同時觀察到： • 6個月緩解持續時間（DOR）率超80%（即超過80%的患者在6個月時仍能維持緩解）； • 患者緩解深度隨時間持續增加； • DOR數據仍在持續成熟中。 維度二：後線NSCLC聯合多西他賽 • 6例患者全部腫瘤縮小，ORR 66.7%，DCR 100%。 儘管目前樣本量有限，但這一結果在同類研究中已非常具有競爭力。 公司計畫進一步擴展至20例患者，以支持後續註冊開發決策。 維度三：一線NSCLC單藥（PD-L1 TPS≥50%） • 16例患者，ORR 81.3%，DCR 100%； • 鱗癌ORR 87.5%，非鱗癌ORR 75%，獲益一致； • 較早時（2026年3月）數據顯示10例患者有9例達到 PR，本次新增的6例患者有4例在首次腫評即達到PR，目前總共已觀察到13例PR； • 所有應答患者均未出現快速進展，患者緩解深度隨時間持續增加。 儘管跨研究比較存在局限性，但當前CS2009單藥在一線NSCLC（PD-L1 TPS≥50%）中的ORR已達到國際同類研究中的領先水準（best-in-class range），顯示出極具競爭力的臨床開發潛力。 註：PD-L1 1%-49%人群數據仍在持續成熟中。 維度四：一線NSCLC聯合化療（鱗癌，PD-L1低表達/陰性） • 截至目前8例鱗癌患者中，7例均為PD-L1≤1%低表達/陰性，1例為PD-L1≤5%低表達，中位年齡70歲； • ORR 75%，DCR 100%；PD-L1陰性患者ORR達100%； 特別值得關注的是： • PD-L1陰性患者中觀察到100%緩解率； • 高齡患者群體中同樣觀察到優異療效。 儘管仍需更長時間隨訪驗證，但已顯示出積極且一致的早期療效信號。 註：一線鱗狀NSCLC聯合化療全人群、一線非鱗狀NSCLC聯合化療仍在入組中，數據後續披露。 五、全球註冊開發策略 CS2009正按照全球多中心開發路徑推進。 • 入組速度極快，數據包準備節奏匹配，與監管溝通節點明確； • 不做單一國家註冊研究，做全球多中心註冊研究（MRCT），所有關鍵註冊研究均採用國際標準治療作為對照組（K藥/K藥+化療/貝伐珠單抗+化療），試驗設計和時間窗口不受當前其他雙抗/三抗競品數據讀出的干擾，具備獨立推進的節奏優勢。 - 2026年10月：與FDA溝通一線NSCLC聯合化療（對比K藥+化療）III期全球註冊臨床方案； - 2026年四季度：與FDA溝通一線mCRC聯合化療（對比貝伐珠單抗+化療）III期全球註冊臨床方案； - 2027年初：與FDA溝通二線NSCLC（聯合多西他賽頭對頭多西他賽）及一線NSCLC單藥頭對頭K藥的III期全球註冊臨床方案。 每個適應症需20-60例POC數據，目前公司已建立支持全球開發的臨床、生產/工藝/品質（CMC）體系，為後續全球多中心III期MRCT研究奠定基礎。 六、2026年重要催化劑 • 2026年8月底：中報更新ASCO後更成熟的臨床數據； • 2026年10月左右：與FDA溝通一線NSCLC聯合化療III期臨床試驗方案； • 2026年四季度：與FDA溝通一線CRC聯合化療III期臨床試驗方案； • 2026年四季度：ESMO會議更新CRC、肺癌等適應症臨床數據； • 2026年底：啟動首批全球III期MRCT註冊研究。 所有關鍵註冊研究均採用當前國際標準治療作為對照組，不依賴競爭產品研究進展。 七、BD進展 目前正與多家跨國藥企（MNC）持續開展深入交流。合作方重點關注：三抗設計邏輯、安全性特徵、NSCLC與CRC臨床數據、全球註冊開發路徑。 隨著數據持續成熟及全球開發計畫推進，CS2009的差異化價值正得到越來越廣泛和高度的認可。 八、管理層信心與市值管理 1、管理層及董事會增持： 近期股價波動明顯偏離公司基本面進展。管理層及董事會表示，將通過增持公司股票表達對CS2009長期價值及公司發展前景的信心。 2、港股通納入預期： 管理層表示，對公司於2026年9月調整窗口納入港股通保持積極預期。 九、核心結論： ASCO 2026數據標誌著CS2009已從機制驗證階段進一步邁向臨床概念驗證（POC）階段。其差異化三抗設計不僅展現出優異的安全性特徵，更在多個傳統I/O冷腫瘤及肺癌人群中持續觀察到具有臨床意義的療效信號與持久緩解。隨著CRC和NSCLC關鍵專案推進全球註冊開發，CS2009正逐步展露成為下一代腫瘤免疫治療骨架藥物的巨大潛力。 關於基石藥業 基石藥業（香港聯交所代碼: 2616）成立於2015年底，是一家專注於腫瘤、免疫與炎症等關鍵疾病領域藥物研發的創新驅動型生物醫藥企業，致力於滿足中國和全球患者的殷切醫療需求。截至目前，公司已成功上市4款創新藥、獲批21項新藥上市申請（NDA）以及9項適應症。當前研發管線均衡配置了抗體偶聯藥物（ADC）、多特異性抗體、以及免疫療法和精準治療藥物在內的16款候選藥物。同時，基石藥業擁有一支資深管理團隊，“全鏈條”覆蓋臨床前探索、臨床轉化、臨床開發、藥物生產、商務拓展、商業運營等關鍵環節。如需瞭解有關基石藥業的更多資訊，請訪問：www.cstonepharma.com。 投資者關係: ir@cstonepharma.com 媒體關係:pr@cstonepharma.com 前瞻性聲明 本文所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請細閱本文，並理解我們的實際未來業績或表現可能與預期有重大差異。本文內所有陳述乃本文章刊發日期作出，可能因未來發展而出現變動。 聲明：僅供醫療衛生專業人士交流使用。 2026-06-12 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 12/06/2026 / 15:02 UTC+8 Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Differentiated Advantages 1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses. • Differentiated CTLA-4 Design: The CTLA-4 component is engineered to avoid excessive activation of peripheral CTLA-4 single-positive T cells, thereby reducing systemic immune toxicity. Combined with VEGF-mediated tumor enrichment, this design preserves the immune-stimulatory benefit of CTLA-4 blockade while substantially improving tolerability. Clinical data has demonstrated that CTLA-4-related toxicities with CS2009 are notably lower than that of conventional CTLA-4 antibody regimens, with immune-related adverse events (irAEs) approaching incidence typically seen with PD-1 monotherapy or PD-1-based bispecific antibodies. • Advantage of Continuous Dosing: Unlike conventional CTLA-4 antibodies, which are often limited to two or three doses due to tolerability concerns, CS2009 can be administered continuously, therefore fully leveraging the CTLA-4 mechanism—not only initiating and enhancing existing anti-tumor T-cell responses but also continuously priming new T-cell clones against newly released tumor antigens throughout treatment. This ongoing expansion of the anti-tumor T-cell repertoire, combined with CS2009’s favorable tolerability, is expected to drive more durable immune responses, prolong clinical benefit, and ultimately improve overall survival. • Pharmacodynamic Validation: Dose-dependent upregulation in ICOS, a recognized pharmacodynamic marker of CTLA-4 pathway activation and T-cell activation, were observed. The ICOS elevation suggests that CS2009 continuously promotes T-cell priming and clonal expansion, validating the biological activity of its CTLA-4 module and providing biological basis for long-term anti-tumor activity. Industry challenge: Historically, most anti-VEGF plus PD-(L)1 regimens have primarily improved progression-free survival (PFS), while overall survival (OS) benefits remains highly uncertain. By incorporating a CTLA-4 mechanism, CS2009 aims to break through this limitation. 2. Low VEGF-Related Toxicity Supporting More Adequate Treatment Exposure and Sustained Clinical Benefit Pharmacodynamic data demonstrated: • Circulating VEGF levels have declined continuously following dosing, and no clear rebound has been observed after up to 147 days of follow-up. This pattern differs from results reported with traditional anti-VEGF antibodies or PD-1/VEGF bispecifics, potentially due to CS2009’s enrichment in the tumor microenvironment and CTLA-4-mediated internalization and clearance of VEGF-antibody complexes. This may reduce reflux of VEGF and its antibody-bound complexes into the peripheral circulation, thereby lowering VEGF-related systemic toxicities such as hypertension and proteinuria. Clinical data demonstrated: • The incidence of Grade ≥3 VEGF-related treatment-related adverse events (TRAEs) is only 5.1%, notably lower than reported rates for certain VEGF-based bispecifics. Industry challenge: VEGF is both a critical efficacy driver and a major source of toxicity in combination therapies. Achieving an optimal balance between efficacy and tolerability, particularly in elderly and high-risk patients, remains a longstanding, unresolved challenge in the VEGF field. 3. Consistent Activity Observed Across Multiple “Cold” Tumors, Highlighting the Value of the CTLA-4 Module and the Trispecific Mechanism Promising anti-tumor activity has been observed in several traditionally immunotherapy-insensitive tumor types, including: Immunotherapy-resistant non-small cell lung cancer (NSCLC), pMMR/MSS metastatic colorectal cancer (mCRC), Soft tissue sarcoma (STS), Non-clear cell renal cell carcinoma (nccRCC). These findings suggest that the combined blockade of PD-1 and CTLA-4, together with VEGF modulation, may enhance T-cell priming, broaden T-cell clonal diversity, promote durable immune memory, and improve T-cell infiltration within the TME—extending immune responsiveness to tumors that were previously I/O-insensitive. The consistent efficacy signals across multiple cold tumors support the ability of CS2009’s PD-1, CTLA-4 and VEGF synergism to reshape the immunosuppressive TME, expand the I/O-benefiting population, and demonstrate the potential to transcend the efficacy boundaries of traditional PD-1 inhibitors and PD-1/VEGF bispecifics. Industry challenge: Effective immunotherapy options remain limited for cold tumors. PD-1 plus CTLA-4 blockade is still one of the most widely recognized strategies for enhancing immunotherapy responsiveness. 4. Consistent Benefit Observed Across Squamous and Non-Squamous NSCLC • Across multiple NSCLC treatment settings, comparable response rates were observed in both squamous and non-squamous patients. CS2009 is showing a trend of consistent benefit across histological subtypes, indicating that its mechanism may not depend on a particular pathologic type and may cover a broader population of NSCLC patients, enhancing the probability of success in future global registrational trials. Industry challenge: Notable differences in efficacy between squamous and non-squamous NSCLC often limit the label expansion and commercial potential of certain products. II. Favorable Safety Profile with Notably Lower VEGF-Related Toxicity Compared with Bispecifics Safety data from the ongoing Phase I study in a mixed tumor population (N=118): • Grade ≥3 TRAE incidence: 24.6%; • Grade ≥3 irAE incidence: 12.7%; • Grade ≥3 VEGF-related TRAE incidence: 5.1%. Focusing on the later-line NSCLC cohort (n=57): • Grade ≥3 TRAE rate: 19.3%; • Grade ≥3 irAE rate: 12.3%; • VEGF-related Grade ≥3 TRAE rate: 5.3%; • Consistent with the safety profile of the overall heavily pretreated mixed-tumor population. Overall: • CTLA-4-related toxicity appears very well controlled. • No new or unexpected safety signals have been identified. • The overall safety profile is comparable to that of PD-1/VEGF bispecific antibodies, while VEGF-related toxicity appears substantially lower. This safety profile provides an important foundation for long-term dosing and future global registrational development. III. Efficacy in “Cold” Tumors Demonstrates Differentiated Clinical Value CS2009 has demonstrated meaningful clinical activity across multiple “cold” tumors, highlighting the differentiated mechanism. 1. Monotherapy in Later-Line pMMR/MSS mCRC • All enrolled patients had heavily pretreated, refractory CRC, including cases with BRAF mutations and right-sided tumors. • CS2009 monotherapy achieved an ORR of 25% and a DCR of 87.5%. Given that ORR in later-line colorectal cancer are typically in the single digits, these results demonstrate clinically meaningful anti-tumor activity. More importantly, efficacy signals emerging in a typical cold-tumor population further supports the differentiated value of the CTLA-4 module. 2. Combination with XELOX in First-Line pMMR/MSS mCRC • The study did not select patients by tumor sidedness, molecular subtype, or liver metastasis; the enrolled population better reflects real-world clinical practice. • To date, all six patients have experienced tumor shrinkage, and three patients achieved a partial response (PR) at their first efficacy assessment. • ORR was 66.7%, and DCR was 100%. Although the sample size remains small, highly consistent early efficacy signals have already been observed, providing positive support for subsequent global registrational development. The Company plans to expand the cohort to approximately 40 patients to generate a more comprehensive proof-of-concept (POC) dataset for upcoming discussions with the global regulatory authorities including the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) on a Phase III global registrational clinical trial. 3. Other “Cold” Tumors • Monotherapy in Later-line Soft Tissue Sarcoma (STS): ORR 33.3%, DCR 66.7%; • Monotherapy in Later-line non-clear cell renal cell carcinoma (nccRCC): ORR 33.3%, DCR 100%;. • Durable responses have also been observed. Notably, the first patient enrolled in Phase I (an Australian female) has experienced sustained tumor shrinkage of more than 40% over 12 months. IV. NSCLC: Multi-Dimensional Data Support Global Registrational Development Dimension 1: Later-Line NSCLC Monotherapy (Pretreated with IO, Chemotherapy, ADCs, or Bispecifics) • Overall ORR in the 30 mg/kg cohort: 24% (squamous 25%, non-squamous 23.1%, consistent benefit); DCR 60%; • In second-line NSCLC (30 mg/kg, post IO + chemotherapy): ORR improved to 30.8%, DCR 84.6%. • In such post-PD-(L)1 patient populations, standard-of-care ORRs are generally low, thus CS2009 has demonstrated competitive single-agent activity. Additional observations include: • 6-month duration-of-response (DOR) rate exceeded 80% (i.e., more than 80% of responders remained in response at 6 months); • Depth of response has continued to deepen over time; • DOR data are still maturing. Dimension 2: Later-Line NSCLC in Combination with Docetaxel • All six evaluable patients experienced tumor shrinkage, resulting in an ORR of 66.7% and a DCR of 100%. Although the sample size is currently small, these results are already very competitive within this class of studies. The company plans to expand the cohort to approximately 20 patients to inform subsequent registrational decisions. Dimension 3: First-Line NSCLC Monotherapy (PD-L1 TPS ≥50%) • Among 16 patients, ORR was 81.3% and DCR was 100%; • Squamous ORR 87.5%, non-squamous ORR 75%, consistent benefit; • Earlier data (March 2026) showed 9 PRs out of 10 patients; among the 6 newly enrolled patients, 4 achieved a PR at their first tumor assessment, bringing the total number of PRs observed to 13; • No responding patients have experienced rapid disease progression, and patients have shown deepening responses over time. While cross-trial comparisons have limitations, CS2009’s single-agent ORR in first-line NSCLC (PD-L1 TPS ≥50%) has reached a best-in-class range among comparable studies globally, demonstrating highly competitive clinical potential. Note: Data in the PD-L1 1%–49% population continue to mature. Dimension 4: First-Line NSCLC in Combination with Chemotherapy (Squamous, PD-L1 Low or Negative) • Among 8 squamous patients enrolled to date, 7 patients have PD-L1 ≤1% (low/negative), and 1 patient has PD-L1 ≤5% (low expression); median age is 70 years; • ORR was 75% and DCR was 100%; among PD-L1-negative patients, ORR reached 100%; Particularly noteworthy: • A 100% response rate was observed among PD-L1-negative patients; • Encouraging efficacy was also observed in elderly patients. Although longer follow-up is required, positive and consistent early efficacy signals are evident. Note: Enrollment is ongoing in the first-line all-comer squamous NSCLC (Chemo Combo) and first-line non-squamous NSCLC (Chemo Combo) cohorts. Data will be disclosed subsequently. V. Global Registration Strategy CS2009 is advancing through a global multi-regional clinical development pathway. • Rapid enrollment supports timely data package generation and regulatory engagement. • Registrational studies will not be conducted in a single country; all key registrational studies will be global multi-regional clinical trials (MRCTs) using current international standard-of-care comparators (pembrolizumab / pembrolizumab + chemotherapy / bevacizumab + chemotherapy). The trial designs and timelines are independent of data readouts from other bispecific/trispecific competitors, giving CS2009 a self-determined development advantage. - October 2026: Discuss the Phase III global registrational clinical trial protocol for first-line NSCLC + chemotherapy (vs. pembrolizumab + chemotherapy) . - Q4 2026: Discuss the Phase III global registrational clinical trial protocol for first-line mCRC + chemotherapy (vs. bevacizumab + chemotherapy) . - Early 2027: Discuss the Phase III global registrational clinical trial protocol for second-line NSCLC (CS2009 + docetaxel vs. docetaxel) and first-line NSCLC monotherapy (head-to-head vs. pembrolizumab) . 20–60 patients of POC data are expected per indication. The company has already established a clinical, CMC (Chemistry, Manufacturing and Controls) and operational system that supports global development, laying the groundwork for subsequent global multi-center Phase III MRCTs . VI. Key Catalysts in 2026 • Late August 2026: Interim results update featuring more mature post-ASCO clinical data. • Around October 2026: FDA discussion regarding the Phase III global registrational clinical trial protocol for first-line NSCLC + chemotherapy. • Q4 2026: FDA discussion regarding Phase III global registrational clinical trial protocol for first-line CRC + chemotherapy. • Q4 2026: ESMO Congress – clinical data updates for CRC, NSCLC, and other indications. • End of 2026: Initiation of the first-wave global Phase III MRCTs. Importantly, all pivotal studies are benchmarked against current global standard-of-care comparators, without dependency on competitors’ development progress. VII. Business Development Progress In-depth discussions are ongoing with multiple multinational pharmaceutical companies (MNCs). Key areas of partner interest include: trispecific antibody design rationale, safety profile, clinical data in NSCLC and CRC, global registration strategy. As data continue to mature and the global development advances, the differentiated value of CS2009 is gaining increasingly broad and strong recognition. VIII. Management Confidence and Capital Markets Initiatives 1. Share Purchases by Management and the Board: Management and the Board believe that the recent share price volatility has significantly deviated from the Company’s fundamental progress. Management and Board members have expressed their confidence in the long-term value of CS2009 and the Company’s growth prospects by increasing their shareholdings. 2. Anticipated inclusion in the Hong Kong Stock Connect Scheme Management expressed a positive expectation that the Company will be included in the Stock Connect scheme at the September 2026 adjustment window. IX. Key Takeaway The ASCO 2026 data mark CS2009’s transition from mechanism validation to the clinical proof-of-concept (POC) stage. Its differentiated trispecific design not only delivers an excellent safety profile, but also consistently generates clinically meaningful efficacy signals and durable responses across a range of traditional I/O-cold tumors and lung cancer populations. As the key CRC and NSCLC programs move toward global registrational development, CS2009 is steadily emerging as a next-generation I/O backbone agent with significant potential. About CStone CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com. IR contact: ir@cstonepharma.com PR contact: pr@cstonepharma.com Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes. 12/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 12/06/2026 / 09:50 UTC+8 Chicago, Illinois - June 12, 2026 - (SeaPRwire) - Lossdog, a new financial technology platform co-founded by Tom Sosnoff and Scott Sheridan, has officially launched in the United States with a mission to give working professionals access to the same quality of compensation data that employers have long used in salary negotiations. The platform offers a single, calculated dollar figure representing a user's professional market worth, expressed as annual salary. Sosnoff and Sheridan previously co-founded thinkorswim, an online brokerage specializing in options trading that was acquired by TD Ameritrade in 2009 for approximately $750 million. The two then co-founded tastytrade, a retail brokerage and financial media network acquired by IG Group in 2021 for $1.1 billion. Lossdog marks their third major fintech venture. The platform works by analyzing a user's resume against real labor market records, including government wage data, to produce a precise professional valuation. Lossdog also includes a portfolio optimization tool that evaluates a user's investment holdings and calculates the lifetime dollar value of underperformance relative to an industry baseline. Research published by Lossdog in early 2026 found that a professional starting at $75,000 per year could leave approximately $3.9 million in uncaptured nominal earnings over a 30-year career, a figure the company attributes to structural information asymmetry in wage negotiation. A follow-up report published in March 2026 found the gap to be significantly wider for female professionals. "Most professionals leave seven figures on the table over their careers because they're negotiating blind," said Jeff Joseph, Chief Strategist at Lossdog. "We built the first AI platform that reads your resume, analyzes your skills and experience against real data, and tells you what you're actually worth down to the dollar." To mark the platform's launch, Lossdog is offering free first-year subscriptions, valued at $100 each, to its first 50,000 registered users. Those users will also share in a $1 million cryptocurrency pool, with individual awards ranging from $50 for the earliest registrants to $10 for those in later waitlist positions. The company has reported more than 25,000 waitlist registrations. Lossdog operates in a space adjacent to platforms such as LinkedIn, Glassdoor, and Payscale, but distinguishes its product by generating an individual-specific figure rather than aggregated salary ranges. The platform currently serves users in the United States. "After 40-plus years on the trading side of the business world, we are about to take on a bigger challenge," Sheridan wrote publicly ahead of the launch. About Lossdog Lossdog is a Chicago-based financial technology company co-founded by Tom Sosnoff and Scott Sheridan. The company offers a subscription-based platform that uses artificial intelligence and government labor market data to calculate the precise professional market value of individual workers and to evaluate the performance of their investment portfolios. Lossdog is currently available to users in the United States. Contact Information Brand: Lossdog Contact: Jeff Joseph Email: jeff.joseph@lossdog.com Website: https://lossdog.com 12/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-11 / 18:43 UTC+8 業績重點 2026財政年度，在品牌轉型的持續推動下，本集團錄得強勁業績。儘管外部不確定性升溫，以及黃金價格出現前所未見的波動，集團仍實現高質量盈利增長。 營業額按年增加5.3%至94,398百萬港元，主要受惠於設計獨特、高毛利的標誌性產品系列銷售貢獻提升。 期內，集團錄得經營溢利按年增長 27.8% 至 18,850 百萬港元，股東應佔溢利增加52.2%至9,004百萬港元，創歷史新高。 毛利率提升至32.3%，乃受惠於黃金價格飆升以及銷售組合轉向較有利的零售業務及設計獨特的首飾。加上強勁業務表現及嚴謹的成本控制，經營溢利率提升360個點子至20.0%，創近五年新高。 本集團的股本回報率上升至28.4%，較過往五年的歷史平均水平20.5%持續提升。 2026年2月，集團於香港開設首間全球旗艦店，並相繼於中國內地（內地）及主要國際市場開設新設計門店，同時將業務拓展至奢華生活時尚領域。 董事會建議派發末期股息每股 0.45 港元，連同中期股息，全年股息每股共 0.67 港元，派息率達 73.4%，反映集團對持續為股東創造回報的堅定承諾。 財務摘要 截至3月31日止年度 2026百萬港元 2025百萬港元 同比變化 營業額 94,398 89,656 +5.3% 毛利 30,500 26,455 +15.3% 毛利率 32.3% 29.5% +280 個點子 經營溢利(1) 18,850 14,746 +27.8% 經營溢利率 20.0% 16.4% +360個點子 本公司股東應佔溢利 9,004 5,916 +52.2% 每股盈利 基本（港元） 0.91 0.59 +53.7% 攤薄（港元） 0.90 0.59 +52.5% 每股全年股息(2) （港元） 0.67 0.52 N/A (1) 毛利及其他收入的合計，減銷售及分銷成本以及一般及行政開支(2) 2026財政年度全年度的派息率約為73.4% （中國香港, 2026年6月11日） 周大福珠寶集團有限公司（「周大福珠寶集團」、「周大福珠寶」、「集團」或「公司」；香港聯交所股份代號︰1929）今天宣布截至2026年3月31日止年度的全年業績（「2026財政年度」）。 業績創歷史新高 充分彰顯品牌轉型成效 2026 財政年度，全球宏觀經濟持續不明朗，金價亦錄得前所未有的波動。儘管面對這些挑戰，集團展現堅實韌性，營業額按年增加5.3%至94,398百萬港元。毛利率上升280個點子至32.3%，乃受惠於黃金價格大幅度波動，以及自2024年起成功推出設計獨特、高毛利的標誌性產品系列銷售貢獻提升所帶動。經營溢利增長27.8%至18,850百萬港元，股東應佔溢利增加52.2%至9,004 百萬港元，創歷史新高。經營溢利率上升360個點子至20.0%，創五年新高。 集團的股本回報率上升至28.4%，較過往五年的歷史平均水平20.5%持續改善。董事會建議派發末期股息每股0.45港元，全年股息每股共0.67港元。2026 財政年度全年派息率約為73.4%。強韌的表現由以客為本的策略及三大關鍵增長動力所推動：（1）重塑中國奢侈品牌的全球地位、（2）強化產品組合及營運效率，以及（3）開拓新領域。 周大福珠寶集團主席鄭家純博士表示：「我們積極加大品牌投入，持續提升品牌吸引力，深化與顧客之間的情感連結，並透過沉浸式零售體驗、精湛工藝及富有感染力的敘事，進一步與全球消費者建立更深共鳴，以及藉數字化互動，展現品牌如何將深厚的歷史與文化藝術底蘊，融匯於當代品味生活之中。」 就全年業績而言，周大福珠寶集團副主席鄭志雯女士表示：「我們欣然見到集團錄得歷史新高業績及高質量盈利，充分印證品牌轉型的成效。作為全球知名中國奢侈品集團，周大福將中式美學、精湛工藝與深厚文化底蘊引領到世界舞台，並為行業樹立新標準。」 重塑中國奢侈品牌的全球地位 全球奢侈品市場一直由西方文化主導。我們致力重塑全球奢華格局，向世界展現當代中國文化、創造力與卓越工藝。周大福成功推出標誌性的萬相系列，充分展現品牌的創新技術及設計創意，成為首個將中國美學與現代工藝巧妙融合的珠寶品牌。萬相系列一經面世即引發市場熱烈追捧，自今年4月開售以來至5月底，的零售值已超過5億港元，比部分標誌性產品系列開售初期成績更為出眾。另外，標誌性產品系列亦發揮吸納新客群的關鍵作用。例如在內地及港澳市場，購買萬相系列的顧客當中，有超過20%為新客。年內，我們推出首個高級珠寶系列「和美東方」，透過植根於文化的世界級工藝弘揚東方美學，並進一步提升品牌在全球高級珠寶領域的影響力。2026 年 3 月，集團委任謝鼎鴻（David Tse）為全球創意總監。他曾任愛馬仕駐中國創意總監，累積了豐富的奢侈品專業經驗，將引領集團的全球故事敘述，進一步深化品牌吸引力。 我們亦持續豐富標誌性產品系列，進一步強化品牌差異化。2026 財政年度， 傳福系列、傳喜系列及周大福故宮系列等標誌性產品系列保持強勁銷售勢頭，合共貢獻集團零售值近100億港元，而經典的傳承系列則貢獻了集團零售值達430億港元。 強化產品組合及營運效率 今年2月，集團於香港尖沙咀廣東道開設全球首間旗艦店，標誌著品牌轉型之旅的重要里程碑。該旗艦店佔地約10,000 呎，是集團在香港及澳門面積最大的門店。此店特設「品牌典藏館」，完美展現我們的歷史文化、工藝及創造力。該旗艦店為顧客帶來升級的零售體驗，體現我們作為世界知名中國奢侈品集團的抱負。 截至2026 年財年底，我們在內地的黃金地段共設8 間新設計的高端形象門店。該等門店的生產力約為平均同店銷售的8 至10 倍，當中定價首飾帶來的貢獻增幅尤其明顯。除了這種店型，我們亦精挑人流暢旺的地段開設門店，同時優化視覺陳列、產品組合及零售體驗。店齡不足兩年的新店平均每月零售值達約1.6 百萬港元，較去年同期大幅增長57%。鑑於新設計的高端形象門店取得理想成效，我們計劃於中國內地開設更多該類門店，由目前的8 間擴展至2030 財政年度的50 間。 內地方面，我們持續推動品牌轉型及優化門店措施， 2026 財政年度的同店銷售上升6.9%。在香港及澳門，內地推行黃金增值稅新政策後，消費者需求顯著增強，2026 財政年度同店銷售增長達16.8%。年內，香港同店銷售增長為13.3%，澳門則為29.4%。 年內，集團進一步加強數字化進程及推出內部開發的AI 智能體平台。我們已於各關鍵職能部門部署超過12 個AI 智能體，涵蓋門店視覺陳列、生成式人工智能珠寶創意中心和人工智能直播等領域，以提升營運效率並優化顧客互動體驗。 開拓新領域 集團為2030 財政年度訂立了遠大的目標，包括相較2026 財政年度，將國際業務的零售值提升一倍，並把國際版圖擴充至100 間門店以上。 配合集團的抱負，我們於2026 財政年度進一步將周大福品牌宇宙拓展至新地域、新渠道、新產品類別及體驗，以契合顧客不斷演變的生活時尚與追求。 本著重新定義全球奢侈品、進一步強化品牌對全球消費者影響力的抱負，集團相繼於新加坡星耀樟宜機場、曼谷暹羅百麗宮，以及首個大洋洲的零售據點 ─ 澳洲悉尼西田購中心開設新設計的高端形象門店，帶動周大福珠寶於其他市場的零售點總數增加至 63 個。2027 財政年度，集團將繼續於東南亞及北美開設更多新設計的高端形象門店，並於未來兩年探索中東市場的發展機會。 集團作為首個進軍奢侈生活時尚領域的全球知名中國珠寶品牌，透過「周大福家居」將工藝、文化傳承及對細節的極致追求，延伸至精緻的家居裝飾與功能性的藝術品之中，包括與知名法國高級瓷器世家Bernardaud 合作推出餐具系列，精妙融合西方工藝與中國文化傳承及黃金藝術。 我們亦推出包括髮飾、金章及錶帶配飾在內的「周大福配飾」，策略性地拓展產品類別。該等生活時尚產品組合旨在開拓多元化的細分市場、擴大客群，並吸引及接觸新顧客，同時與我們的核心珠寶業務產生強大的協同效應。 2026 財政年度，我們持續積極推動與知名IP跨界合作，以觸及更廣泛的新客群。我們與《黑神話》的聯乘系列廣受市場熱烈歡迎，其男性顧客佔比顯著高於集團平均水平。同時，集團與迪士尼、Chiikawa及NBA的聯乘項目亦成功吸納新會員，相關IP產品的顧客中約有35%至55%為新會員，當中不乏年輕一代。 集團旗下的HEARTS ON FIRE 於年內持續推動轉型，鞏固其作為當代鑽石珠寶品牌的定位。品牌年內展現穩健表現，其標誌性 INSIDE/OUT 系列貢獻品牌全球收入的 13%。同時，品牌亦新增5個零售點以拓展亞洲零售版圖，進一步在多個重點奢侈品市場提升知名度。 業務展望 集團品牌轉型策略的成效，充分體現在2026 財政年度穩健的財務及營運表現，以及2027 財政年度至今持續展現的韌性。 我們現正邁入數年轉型旅程中的關鍵階段，朝著2029 年百年里程碑邁進。我們將於2027 財政年度及其後加快步伐，並確保策略執行更具精準度與全面，重點聚焦於提升品牌吸引力、優化零售體驗及加強產品差異化。 儘管外部環境仍存在波動及宏觀經濟不確定性，我們對所營運市場持審慎樂觀態度。我們將堅定推進品牌轉型進程 – 重塑中國奢侈品牌的全球地位、強化產品組合及營運效率，以及開拓新領域。 集團將持續嚴格執行財務紀律，加強成本及資本管理，推動高質量增長，並為股東創造可持續的盈利及回報。 2030 財政年度的抱負 在品牌邁向百年里程碑之際，我們正致力構築一個以珠寶融入顧客品味生活的周大福品牌宇宙，進一步深化顧客對文化傳承、藝術美感與精湛工藝的欣賞與共鳴。我們深信，奢華是一種跨越地域與文化的共通語言，而珠寶與品味生活的融合，正是對美學、優雅與創意的共同詮釋。 展望2030年，我們為訂立了以下目標： 財務表現：我們旨在實現高於市場的營業額增長，並於2030財政年度維持25%以上的高股本回報率； 門店網絡升級：我們計劃於2030 財政年度完成零售點的全面翻新與升級，務求在所有地點提供一致且具備鮮明特色的零售體驗。同時，我們計劃於中國內地開設更多新設計的高端形象門店，數量將會從目前的8間大增至2030 財政年度的50 間； 擴張國際市場：目標將國際業務的零售值較2026 財政年度提升一倍，並將國際市場門店擴張至逾 100 間； 可持續發展：我們的目標是以2024 財政年度，即我們品牌轉型的起始年度為基準年，於2030 財政年度前將溫室氣體排放量減少50%。 ### 關於周大福珠寶集團有限公司 周大福珠寶集團的旗艦品牌「周大福」創立於1929年，一直透過別出心裁的設計和對細節的堅持，讓傳統成為經典。時至今日，品牌已成為了卓越品質、非凡價值及誠信可靠的代名詞。 作為全球知名中國奢侈品集團，我們深信透過現代創新設計揉合傳統工藝，能創造出代代相傳的臻品。每個系列皆承載顧客的人生故事，慶祝他們生命中每個珍貴時刻，並在追尋幸福的旅程中帶來啟發和激勵，讓「周大福」的品牌故事深深融入顧客的生活脈絡。 集團擁有豐富的品牌組合，除了旗艦品牌「周大福」，還有HEARTS ON FIRE、ENZO與MONOLOGUE。我們亦積極開拓IP 聯乘合作，為顧客提供多元化的選擇。我們的業務網絡遍布中國，且持續延伸至全球多個市場。在全球設有逾5,000 家門店，致力於全渠道為顧客提供無縫體驗。 周大福珠寶集團有限公司（香港聯交所股份代號：1929）於2011 年12 月在香港聯合交易所主板上市，致力通過提高盈利質量和推動更高價值的增⾧，為不同持份者創造可持續的⾧期價值。 傳媒垂詢，請聯絡： 周大福珠寶集團有限公司吳海廸（Haide Ng） 企業傳訊副總監 電話：（852）3115 4402 電郵：haideng@chowtaifook.com 2026-06-11 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 11/06/2026 / 18:43 UTC+8 Results Highlights Chow Tai Fook Jewellery delivered strong FY2026 performance on the back of successful brand transformation, achieving high-quality earnings growth against macro uncertainties and significant gold price volatility. Revenue grew 5.3% to HK$94,398 million, underpinned by steady growth from design-led and higher-margin iconic collections. The Group achieved an operating profit of HK$18,850 million (+27.8% YoY) and a record high profit attributable to shareholders of HK$9,004 million (+52.2% YoY). Gross profit margin expanded to 32.3%, supported by higher gold prices and increased contribution from the retail business and design-led jewellery. Operating profit margin expanded 360bps to a five-year high level of 20.0% driven by strong business performance and continued disciplined cost management. Return on Equity ("ROE") increased to 28.4%, which represented a sustained improvement against our 5-year historical average of 20.5%. The Group opened its first global flagship store in Hong Kong in February 2026, alongside newly designed stores across the Chinese Mainland and key international markets, while expanding into luxury lifestyle categories. The Board has proposed a final dividend of HK$0.45 per share, bringing the full-year total to HK$0.67 per share, a payout ratio of 73.4%, reflecting our commitment to sustained shareholder returns. Financial Summary For the year ended 31 March 2026HK$ million 2025HK$ million YoY Change Revenue 94,398 89,656 +5.3% Gross profit 30,500 26,455 +15.3% Gross profit margin 32.3% 29.5% +280 bps Operating profit(1) 18,850 14,746 +27.8% Operating profit margin 20.0% 16.4% +360 bps Profit attributable to shareholders of the Company 9,004 5,916 +52.2% Earnings per share Basic (HK$) 0.91 0.59 +53.7% Diluted (HK$) 0.90 0.59 +52.5% Full year dividend per share(2) (HK$) 0.67 0.52 N/A (1) Aggregate of gross profit and other income, less selling and distribution costs and general and administrative expenses (2) The payout ratio for FY2026 approximated 73.4% (Hong Kong, China, 11 June 2026) Chow Tai Fook Jewellery Group Limited (“Chow Tai Fook Jewellery Group”, the “Group” or the “Company”; SEHK stock code: 1929), today announces its annual results for the year ended 31 March 2026 ("FY2026"). Record Results Underscore the Continued Success of Brand Transformation The Group demonstrated strong resilience as revenue grew 5.3% to HK$94,398 million in a year marked by macroeconomic uncertainty and significant gold price volatility. Gross profit margin of 32.3% was up 280bps, driven by the surge in gold price and a higher contribution from the design-led and higher- margin iconic collections, successfully launched since 2024. Operating profit grew 27.8% to HK$18,850 million and profit attributable to shareholders grew 52.2% to a record high HK$9,004 million. Operating profit margin of 20.0% was up 360 bps to a five-year high level. The Group’s Return on Equity ("ROE") increased to 28.4%, which represented a sustained improvement against our 5-year historical average of 20.5%. The Board has proposed a final dividend of HK$0.45 per share, bringing the dividend per share for the year to HK$0.67, a full-year payout ratio of 73.4%. The strong performance was powered by a customer centric approach driven by three key levers of growth: (1) Redefining Chinese luxury globally, (2) Rejuvenating portfolio and operational efficiency and (3) Reimagining new horizons. Dr. Henry Cheng, Chairman of Chow Tai Fook Jewellery Group, said, “We are committed to investing boldly in our brand – elevating desirability, forging deeper emotional connection with customers, and expanding our global resonance through immersive retail experience, exquisite craftsmanship, compelling storytelling and digital engagement that blends our rich heritage and cultural artistry with contemporary lifestyle.” Commenting on the annual results, Ms. Sonia Cheng, Vice-chairman of Chow Tai Fook Jewellery Group, said, “We are delighted that the Group achieved record high results and high-quality earnings, validating the success of our brand transformation. As a leading global Chinese luxury group, Chow Tai Fook is charting a course to bring Chinese aesthetics, craftsmanship, and heritage storytelling to the world stage while setting a new benchmark for the industry. Redefining Chinese Luxury Globally The global luxury landscape has been dominated by Western culture. Our ambition is to redefine Chinese luxury globally, showcasing the contemporary Chinese culture, innovation and exquisite craftsmanship to the world. The successful launch of our signature collection – DAWN Collection, has clearly demonstrated Chow Tai Fook’s innovation and creativity, being the first jewellery brand to blend Chinese aesthetics with modern craftsmanship. Since its launch in April 2026 till the end of May 2026, DAWN Collection has delivered remarkable initial results, with Retail Sales Value (“RSV”) of over HK$500 million, outperforming the debut of some of the signature collections to date. Furthermore, more than 20% of customers purchasing this Collection were new to us in the Chinese Mainland, Hong Kong and Macao, underscoring the effectiveness of our signature collections in driving new customer acquisition. During the year, we unveiled our first High Jewellery Collection, “Timeless Harmony”, championing Eastern aesthetics through culturally rooted, world‑class craftsmanship and expanding the brand’s presence in the global high jewellery segment. In March 2026, we appointed David Tse as Global Creative Director, bringing deep luxury expertise from his tenure as Creative Director at Hermès in China, to lead our global storytelling and deepen brand desirability. Blending heritage with contemporary designs, our signature collections continue to resonate with the growing base of culturally conscious consumers. The Rouge Collection, Joie Collection and Chow Tai Fook Palace Museum Collection sustained strong sales momentum in FY2026, contributing close to HK$10 billion to our RSV, while the iconic HUÁ Collection contributed HK$43 billion to our RSV. Rejuvenating Portfolio and Operational Efficiency In February 2026, the Group opened its first global flagship store on Canton Road in Tsim Sha Tsui, Hong Kong, marking a significant milestone in its brand transformation journey. The approximately 10,000-square-foot flagship is the Group’s largest store across Hong Kong and Macao, showcasing the brand’s nearly century-long legacy, craftsmanship and creativity through it’s “Heritage Pavilion” and diverse offerings. The flagship offers consumers an elevated retail experience that reflects our evolving ambition as the leading global Chinese luxury group. As of FY2026, we had a total of 8 newly designed luxury-format stores in prime locations in the Mainland. These stores delivered significantly higher productivity, which was approximately 8 to 10 times the average Same Store Sales (“SSS”). These newly designed stores also had a substantially higher contribution from fixed-price jewellery. We also selectively opened stores in high-footfall locations, backed by enhanced visual merchandising, optimised product mix and elevated retail experience. As a result, the average monthly RSV of new stores aged less than two years reached approximately HK$1.6 million, up 57% YoY. In view of the success of the newly designed luxury-format stores, we plan to expand its network in the Mainland from the current 8 stores to 50 by FY2030. In the Mainland, SSS increased by 6.9% in FY2026, supported by our ongoing brand transformation initiatives and continued store optimisation. In Hong Kong and Macao, consumer demand strengthened notably post Mainland VAT reform on gold trading, with SSS rising 16.8% in FY2026. SSS growth in Hong Kong was 13.3% and Macao was 29.4% for the year. During the year, the Group also advanced digitalisation and launched our in-house AI Agent platform, deploying over 12 agents across functions such as visual merchandising, the GenAI jewellery creative centre, and AI live streaming, to drive operational efficiency and enhance customer engagement. Reimagining New Horizons The Group’s FY2030 ambition is to double the RSV of our international operations compared to FY2026; and to have an international footprint of over 100 stores. In line with our ambition, the Group expanded the Chow Tai Fook universe into new geographies, channels, product categories, and experiences that resonate with the constantly evolving lifestyle and aspirations of customers in FY2026. With the ambition to reshape global luxury and further strengthen our brand influence among global audiences, newly designed luxury-format stores were launched at Jewel Changi Airport in Singapore, Siam Paragon in Bangkok, and Westfield Sydney in Australia – marking our first entry into Oceania. This brings the total number of CHOW TAI FOOK JEWELLERY POS in Other Markets to 63. In FY2027, we will open further newly designed luxury-format stores across Southeast Asia and North America, while exploring opportunities in the Middle East in the next two years. As the first global Chinese jewellery brand to enter the luxury lifestyle arena, the new luxury home-décor line “Chow Tai Fook Home” brings craftsmanship, cultural heritage and attention to detail to refined home décor and functional art, including tableware collections developed in collaboration with renowned French porcelain house Bernardaud, where Western craftsmanship meets Chinese cultural heritage and gold artistry. Together with CTF Accessories which covers hair adornments, gold medallions and watch strap accessories, the new lifestyle offers will capture diverse market segments, broaden our customer base and create synergies with our core jewellery business. In FY2026, we continued to collaborate proactively with renowned IPs to reach new audiences. Our Black Myth Collection received overwhelming market response, with a significantly higher male mix than the Group average. Meanwhile, collaborations with Disney, Chiikawa and the NBA attracted new loyalty members, which accounted for 35%–55% of these IP collaborations’ customers, with a significant percentage of younger generations. HEARTS ON FIRE, a member of the Group, has continued its transformation into a modern global luxury diamond jewellery brand within the Group. During the year, HEARTS ON FIRE delivered resilient performance with its iconic INSIDE/OUT Collection contributing to 13% of the brand’s global revenue. The brand also expanded its retail presence in Asia with five new luxury retail locations, strengthening visibility in key luxury markets. Business Outlook The strong financial and operational performance highlights the success of our brand transformation strategy and paves the way for further growth. We are now entering the definitive phase of our multi-year transformation journey to our centenary in 2029, accelerating the pace and ensuring the precision of our full-scale strategic execution in FY2027 and beyond. Our sharpened focus is on elevating brand desirability, enriching the retail experience, and strengthening product differentiation. Despite continuing external market volatility and macroeconomic uncertainty, we remain cautiously optimistic in the markets where we operate. We are firmly committed to our brand transformation journey – redefining Chinese luxury globally, rejuvenating portfolio and operational efficiency and reimagining new horizons. We will continue to rigorously uphold financial discipline in cost and capital management, driving high-quality growth, sustainable earnings and returns for our shareholders. FY2030 Ambitions As we approach our centenary, we envision a Chow Tai Fook universe where jewellery seamlessly intertwines with the lifestyle of our customers – enriching their appreciation of cultural heritage, artistry, and craftsmanship. We see luxury as a universal language that transcends borders and cultures, where jewellery and lifestyle come together to express a shared vision of beauty, elegance, and creativity. Looking ahead to FY2030, we have set out the following ambitious targets: Financial performance: We aim to achieve above-market revenue growth, and sustain a high ROE of above 25% by FY2030; Store network evolution: We target to complete the full renovation and elevation of our POS portfolio by FY2030, delivering a cohesive and distinctive retail experience across all locations. In parallel, we plan to expand our network of newly designed luxury-format stores in the Mainland from the current 8 stores to 50 by FY2030; International expansion: We aim to double the RSV of our international operations compared to FY2026; and to have an international footprint of over 100 stores. Sustainability: We will target a 50% reduction in Greenhouse Gas emissions by FY2030, using FY2024, the first year of our brand transformation journey, as the base year. ### Chow Tai Fook Jewellery Group Limited Since its founding in 1929, CHOW TAI FOOK, the flagship brand of Chow Tai Fook Jewellery Group, has been celebrated for its bold designs and meticulous attention to detail. Our commitment to innovation and craftsmanship has made us synonymous with excellence, value, and authenticity. As the global Chinese luxury group, we blend contemporary designs with traditional techniques to create timeless pieces. Each collection reflects our customers' stories and lives, celebrating their special moments. We aspire to inspire and captivate generations to come, weaving the story of CHOW TAI FOOK into their own. Our brand portfolio includes the iconic CHOW TAI FOOK flagship brand, HEARTS ON FIRE, ENZO, and MONOLOGUE, offering a wide variety of products that also includes an expanding range of cutting-edge IP collaborations. With over 5,000 stores worldwide, we offer a seamless client journey across all touchpoints that includes a network across China as well as a growing number of global locations. Chow Tai Fook Jewellery Group Limited (SEHK: 1929) has been listed on the Main Board of the Hong Kong Stock Exchange since December 2011. We are committed to delivering sustainable long-term value for our stakeholders by continually enhancing earnings quality and driving higher value growth. Media Enquiries: Chow Tai Fook Jewellery Group Limited Haide Ng Associate Director, Corporate Communications Tel: (852) 3115 4402 Email: haideng@chowtaifook.com 11/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 09/06/2026 / 16:00 UTC+8 (9 June 2026, Hong Kong) Waton Financial Limited Unveils MoTA: An AI-Native Investment Team Operating System and Agent Marketplace That Lets Anyone Build, Manage, and Command Their Own Professional Investment Research Team Waton Financial Limited today unveiled MoTA (Manager of Trading Agents), an AI-native investment team operating system and Agent marketplace that redefines what AI can do for investors. MoTA is not a stock-picking chatbot or a black-box trading bot. It is a platform designed to let users build, manage, and command their own team of specialized AI Agents across the full investment workflow — from portfolio definition to trade execution. The Problem Professional investment research has always required a team: factor researchers, fundamental analysts, technical analysts, risk managers, portfolio constructors, and trade execution officers. Each role demands specialized talent and expensive infrastructure. For individual investors and small teams, assembling such a capability has been cost-prohibitive — until now. The Solution MoTA transforms the user from a passive consumer of AI signals into an active leader of an AI-powered investment team. Its four integrated modules work together to deliver a seamless, end-to-end experience. First, Talents — the Agent Marketplace. Users browse, compare, and hire specialized AI Agents by role. Each Agent is purpose-built for a specific investment function — fundamental analysis, technical analysis, risk management, trade execution, and more. Agents can be swapped and composed as strategies evolve. Second, Team — composing your investment team. Users assemble multiple Agents into a structured team. Analysts feed research inputs, the Portfolio Manager evaluates and writes memos, the Risk Manager reviews exposure, and the Trader validates routing. The human user retains final sign-off authority at every stage. Third, Portfolio — the portfolio cockpit. A real-time overview of holdings, assets, P&L, risk, and exposure. Users see exactly what is moving across positions, where risk sits, and where returns originate — all in one unified view. Fourth, Decision — the Decision Center. Every Agent-generated suggestion surfaces in the Decision Center with full context: source Agent, signal, reasoning, and current status. Users can click into the full workflow or execution path, compare competing analyses, and manage an actionable queue of decisions. Every recommendation is structured, traceable, and auditable. These four modules connect in a continuous workflow: Portfolio to Decision to Team to Trade. Why MoTA Is Different Traditional AI investing tools offer a single AI chat box, scattered research answers, black-box signals, no role separation, and AI value that is hard to measure. Reviews are tied to AI silos. MoTA provides a multi-Agent investment team, a connected Portfolio-to-Trade workflow, an auditable Decision Center, dedicated Analyst and PM and Risk and Trader roles in coordination, unified metrics such as ROI and win rate and cost per run and override rate, and a unified path for portfolio, decisions, Agents, and trades. The Vision Behind MoTA Waton Financial Limited's mission with MoTA is clear: to make professional-grade multi-agent investing tools more accessible, more transparent, and more user-controlled. MoTA does not replace human judgment — it amplifies it. The platform frees users from the burden of being a full-stack investment expert and elevates them to a higher role: the builder, manager, and decision-maker of their own AI investment team. As AI moves from content generation into workflow execution, investing — inherently a multi-role, multi-step, multi-constraint process — is a natural fit for this transformation. MoTA is designed to bridge the gap between what AI can do and what the investment workflow actually needs. About MoTA MoTA (Manager of Trading Agents) is Waton Financial Limited's flagship AI-native investment team operating system and marketplace for specialized investing Agents. It enables users to create fully customizable investment teams, assign specialized AI Agents to each role, and receive structured, traceable, and auditable investment suggestions across the entire Portfolio-to-Trade workflow. About Waton Financial Limited Waton Financial Limited is a publicly listed financial services and technology company that designs, owns, and operates the MoTA platform. Waton is committed to building AI-native infrastructure for investment teams and making professional-grade multi-agent investing tools accessible to a broader audience. Welcome to MoTA. Welcome to the new era of investing. Media Contact Email: ir@watonfinancial.com Website: https://wtf.us Explore MoTA: https://mota.ai Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those expressed or implied. This is not investment advice. Past performance does not guarantee future results. 09/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-08 / 10:13 UTC+8 千百度（1028.HK）在6月5日宣佈，將通過收購股權並認購新股，取得國內領先 AI 數據服務商本原智數的控股權益，並納入合併報表，形成「鞋履 + 人工智慧數據」雙主業。 為什麼是數據？當公開數據被大模型逐漸消化，AI 的關鍵瓶頸正從「誰的模型更大」，轉向「誰能持續提供更難、更真實的高品質數據」。算力可以採購，演算法可以複現，唯獨這件事買不到、也快不了。2025 年 Meta 以約 290 億美元估值入股 Scale AI，正是市場對這一判斷的重新定價。 本原智數的稀缺，在於它的位置和它的盈利。成立於 2015 年，處於 AI 產業鏈上游，是國內少數同時具備大模型、世界模型與具身智慧完整數據服務能力的供應商之一；服務頭部大模型廠商、一線互聯網平台與領先具身智慧企業，並在若干高價值數據品類上擔任獨家供應商。2025 年收入約 1.562 億元，稅後淨利1,110 萬元，2026 年前五個月收入強勁增長。在普遍依賴燒錢的 AI 行業，一家手握真實訂單、且已盈利的數據公司本就稀缺。 這筆交易的設計也頗具巧思：以千百度內部資源支付，鞋履主業現金流穩健、維持淨現金；認購新股的對價投入產能與研發，創始團隊保留權益。交易完成後，本原智數保持獨立品牌、獨立運營與數據隔離——千百度不做模型、不與其客戶競爭，互為對手的行業客戶得以繼續放心使用同一家中立供應商。 千百度管理層表示：「我們相信，高品質數據是人工智慧時代最關鍵、也最稀缺的基礎設施之一。本次交易使集團以穩健的消費實業為基礎，切入這一高速增長的領域。我們將與本原智數一道，長期為中國 AI 產業提供高品質的數據燃料，在雙主業格局下為股東創造可持續的長期價值。」 2026-06-08 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

EQS via SeaPRwire.com / 08/06/2026 / 10:13 UTC+8 On June 5, 2026, C.banner (01028.HK) announced that it will obtain controlling interests in Benyuan Zhishu, a leading domestic AI data service provider, through equity acquisition and new share subscription. Benyuan Zhishu will be consolidated into the Group’s financial statements, marking the formation of a dual-core business structure comprising “footwear+ Artificial Intelligence data”. Why data? As public data is gradually digested by large models, the critical bottleneck in AI is shifting from “whose model is bigger” to “who can continuously provide harder, more authentic, high-quality data.” Computing power can be purchased, algorithms can be replicated, but this particular task cannot be bought or expedited. In 2025, Meta invested in Scale AI at a valuation of approximately $29 billion, marking a market revaluation of this insight. The scarcity of Benyuan Zhishu lies in its position and profitability. Founded in 2015, it sits upstream in the AI industry chain and is one of the few domestic suppliers that possess comprehensive data service capabilities, including large models, world models, and embodied intelligence. It serves top-tier large model manufacturers, leading internet platforms, and eminent embodied intelligence enterprises, acting as an exclusive supplier in several high-value data categories. Its revenue in 2025 was approximately 156.2 million yuan, with a net profit of 11.1 million yuan after tax, and the first five months of 2026 have shown strong revenue growth. In an AI industry largely reliant on burning money, a data company equipped with real orders and already profitable is indeed rare. The design of this transaction also demonstrates ingenuity: it is funded entirely with the Group’s internal resources. C.banner’s footwear business generates solid cash flow and maintains a net cash position. Proceeds from the new share subscription will be invested into capacity expansion and R&D, while the founding team will retain equity holdings. Upon completion of the transaction, Benyuan Zhishu will retain its independent brand, independent operations, and data segregation. C.banner will not develop models or compete with Benyuan Zhishu’s clients, allowing industry competitors to continue using the same neutral supplier with confidence. The management of C.banner stated: “We believe that high-quality data is one of the most critical and scarce infrastructures in the era of artificial intelligence. This transaction allows the Group to enter this rapidly growing sector while maintaining a stable foundation in the consumer industry. We look forward to working with Benyuan Zhishu to continuously provide 'data fuel' of high quality to China's AI industry, creating sustainable long-term value for our shareholders under the dual-core business framework.” 08/06/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com

EQS via SeaPRwire.com / 2026-06-04 / 19:30 UTC+8 [2026年6月4日 – 香港] 領先的全球化社交娛樂公司 – 赤子城科技有限公司（「赤子城科技」或「本公司」，股份代號：9911；連同其附屬公司統稱「本集團」）發佈公告稱，公司已註銷此前於2026年4月27日至5月29日期間購回的合共517.4萬股股份，涉及總回購金額約4,532萬港元。 此前，赤子城科技於2026年3月宣佈，計畫未來兩年斥資約3億港元在市場上進行股份回購。公告顯示，本次註銷後，赤子城科技已發行股份總數將由14.13208391億股減少至14.08034391億股，公司不再持有任何庫存股份。 赤子城科技董事會表示，註銷購回股份將提高每股股份資產淨值及每股股份盈利，符合公司及股東整體利益，董事會將繼續不時檢討及全權酌情決定進行股份購回。公司近期已連續推進回購及註銷動作，向市場釋放出管理層對公司長期發展前景的信心，也體現出其對股東回報和資本效率的重視。 自今年3月納入港股通以來，赤子城科技累計成交額大幅提升，南向資金參與熱情持續升溫。從回購時點看，此輪回購正值公司一季報發佈後。4月22日，赤子城科技披露2026 年第一季度未經審核營運資料，期內總收入預期約人民幣20.30至21.30億元，同比增長約33.0%至39.6%。其中，核心社交業務同比增長約31.3%至37.2%；創新業務同比增長約46.7%至58.7%，主要得益於AI驅動下短劇業務的快速增長。 有關赤子城科技 赤子城科技是一家全球化的互聯網公司，2019年在港交所主板上市，股票代碼為09911.HK。公司以「創造美好情緒價值」為願景，在社交、遊戲等領域打造了數十款面向全球用戶的APP，包括泛人群社交產品 MICO、YoHo、TopTop、SUGO；多元人群社交產品 HeeSay；精品遊戲產品 Alice's Dream: Merge Games等，累計服務過上百個國家和地區的超過10億全球用戶。赤子城科技深耕中東北非市場，並積極佈局東南亞、歐美、日韓等地區，致力於成為全球最大的社交娛樂公司。 如欲查詢更多資訊，請聯絡： DLK Advisory pr@dlkadvisory.com 2026-06-04 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php